Oxidative phosphorylation as a target space for tuberculosis: success, caution, and future directions

Cook, Gregory M.; Hards, Kiel; Dunn, Elyse; Heikal, Adam; Nakatani, Yoshio; Greening, Chris; Crick, Dean C.; Fontes, Fabio L.; Pethe, Kevin; Hasenoehrl, Erik; Berney, Michael

2017

Cook, G. M., Hards, K., Dunn, E., Heikal, A., Nakatani, Y., Greening, C., . . . Berney, M. (2017). Oxidative Phosphorylation as a Target Space for Tuberculosis: Success, Caution, and Future Directions. *Microbiology Spectrum*, 5(3).
doi:10.1128/microbiolspec.TBTB2-0014-2016

<https://hdl.handle.net/10356/88834>

<https://doi.org/10.1128/microbiolspec.TBTB2-0014-2016>

© 2017 American Society for Microbiology. This paper was published in *Microbiology Spectrum* and is made available as an electronic reprint (preprint) with permission of American Society for Microbiology. The published version is available at: [<http://dx.doi.org/10.1128/microbiolspec.TBTB2-0014-2016>]. One print or electronic copy may be made for personal use only. Systematic or multiple reproduction, distribution to multiple locations via electronic or other means, duplication of any material in this paper for a fee or for commercial purposes, or modification of the content of the paper is prohibited and is subject to penalties under law.

Oxidative Phosphorylation as a Target Space for Tuberculosis: Success, Caution, and Future Directions

GREGORY M. COOK,^{1,2} KIEL HARDS,¹ ELYSE DUNN,¹
ADAM HEIKAL,^{1,2} YOSHIO NAKATANI,^{1,2} CHRIS GREENING,^{3,4}
DEAN C. CRICK,⁵ FABIO L. FONTES,⁵ KEVIN PETHE,⁶
ERIK HASENOEHRL,⁷ and MICHAEL BERNEY⁷

¹University of Otago, Department of Microbiology and Immunology, Otago School of Medical Sciences, Dunedin, New Zealand; ²Maurice Wilkins Center for Molecular Biodiscovery, The University of Auckland, Auckland 1042, New Zealand; ³The Commonwealth Scientific and Industrial Research Organization, Land and Water Flagship, Acton ACT, Australia; ⁴Monash University, School of Biological Sciences, Clayton VIC, Australia; ⁵Colorado State University, Department of Microbiology, Immunology, and Pathology, Fort Collins, CO 80523; ⁶Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore; ⁷Albert Einstein School of Medicine, Department of Microbiology and Immunology, Bronx, NY 10461

ABSTRACT The emergence and spread of drug-resistant pathogens, and our inability to develop new antimicrobials to combat resistance, have inspired scientists to seek out new targets for drug development. The *Mycobacterium tuberculosis* complex is a group of obligately aerobic bacteria that have specialized for inhabiting a wide range of intracellular and extracellular environments. Two fundamental features in this adaptation are the flexible utilization of energy sources and continued metabolism in the absence of growth. *M. tuberculosis* is an obligately aerobic heterotroph that depends on oxidative phosphorylation for growth and survival. However, several studies are redefining the metabolic breadth of the genus. Alternative electron donors and acceptors may provide the maintenance energy for the pathogen to maintain viability in hypoxic, nonreplicating states relevant to latent infection. This hidden metabolic flexibility may ultimately decrease the efficacy of drugs targeted against primary dehydrogenases and terminal oxidases. However, it may also open up opportunities to develop novel antimycobacterials targeting persister cells. In this review, we discuss the progress in understanding the role of energetic targets in mycobacterial physiology and pathogenesis and the opportunities for drug discovery.

OVERVIEW OF RESPIRATION AND OXIDATIVE PHOSPHORYLATION IN *MYCOBACTERIUM TUBERCULOSIS*

The genus *Mycobacterium* comprises a group of obligately aerobic bacteria that have adapted to inhabit a wide range of intracellular and extracellular environments. Fundamental to this adaptation is the ability to

Received: 9 February 2016, **Accepted:** 31 March 2017,
Published: 9 June 2017

Editors: William R. Jacobs Jr., Howard Hughes Medical Institute, Albert Einstein School of Medicine, Bronx, NY 10461; Helen McShane, University of Oxford, Oxford OX3 7DQ, United Kingdom; Valerie Mizrahi, University of Cape Town, Rondebosch 7701, South Africa; Ian M. Orme, Colorado State University, Fort Collins, CO 80523.

Citation: Cook GM, Hards K, Dunn E, Heikal A, Nakatani Y, Greening C, Crick DC, Fontes FL, Pethe K, Hasenoehl E, Berney M. 2017. Oxidative phosphorylation as a target space for tuberculosis: success, caution, and future directions. *Microbiol Spectrum* 5(3): TBTB2-0014-2016. doi:10.1128/microbiolspec.TBTB2-0014-2016.

Correspondence: Greg Cook, gregory.cook@otago.ac.nz
© 2017 American Society for Microbiology. All rights reserved.

respire and generate energy from variable sources and to sustain metabolism in the absence of growth. The pioneering work of Brodie and colleagues on *Mycobacterium phlei* established much of the primary information on the electron transport chain and oxidative phosphorylation system in mycobacteria (reviewed in 1). Mycobacteria can only generate sufficient energy for growth by coupling the oxidation of electron donors derived from organic carbon catabolism (e.g., NADH, succinate, malate) to the reduction of O₂ as a terminal electron acceptor. Mycobacterial genome sequencing revealed that branched pathways exist in mycobacterial species for electron transfer from many low-potential reductants, via quinol, to oxygen (Fig. 1).

During aerobic growth, electrons are transferred to oxygen via two terminal respiratory oxidases: an *aa*₃-type cytochrome *c* oxidase (encoded by *ctaBCDE*) belonging to the heme-copper respiratory oxidase family and cytochrome *bd*-type menaquinol oxidase (*cydABCD*) (Fig. 1). Despite the acknowledged importance of oxygen in the physiology and pathobiology of *M. tuberculosis*, the molecular mechanisms governing

the regulation of terminal oxidase expression remain largely unknown. In the absence of oxygen, mycobacterial growth is inhibited, even if alternative electron acceptors are present (e.g., nitrate, fumarate). Despite growth being inhibited, mycobacteria are able to metabolize exogenous and endogenous energy sources under low oxygen for maintenance functions. The electron acceptors and mechanisms to recycle reducing equivalents under these conditions are poorly understood. ATP synthesis is obligatorily coupled to the electron transport chain and the F₁F₀-ATP synthase, irrespective of the oxygen concentration or the proton motive force (PMF), but the reasons for this remain unexplained. The aim of this review is to discuss the progress in understanding the role of energetic targets in mycobacterial physiology and pathogenesis and the opportunities for drug discovery.

TARGETING THE PMF IN *M. TUBERCULOSIS*

All bacteria require a PMF to grow and remain viable under replicating and nonreplicating conditions. During

FIGURE 1 Generalized schematic overview of relevant electron transfer components of *M. tuberculosis*. Complexes indicated in blue oxidize various substrates to reduce quinones. The resulting (mena)quinol molecules (orange) can be oxidized to result in reduction of various terminal electron acceptors, mediated by the complexes shown in purple.

respiration, energy is conserved by the generation of a PMF across a proton-impermeable membrane. The PMF (electrochemical potential) consists of two gradients: an electrical potential ($\Delta\psi$), due to the charge separation across the membrane (positive_{outside}/negative_{inside}), and a chemical transmembrane gradient of protons (ΔpH , acidic_{outside}/alkaline_{inside}) (Fig. 2). At neutral pH, the PMF is predominantly in the form of a $\Delta\psi$, but as the external pH drops, the ΔpH increases and the $\Delta\psi$ decreases to maintain a constant PMF. Dissipation of the PMF leads to a rapid loss of cell viability and cell death.

A variety of mechanisms are used to generate the PMF in mycobacteria (Fig. 2). Mycobacteria generally grow at neutral pH and under these conditions generate a PMF of approximately -180 mV (2). Under hypoxia, *M. tuberculosis* generates a total PMF of -113 mV (-73 mV of $\Delta\psi$ and -41 mV of $Z\Delta\text{pH}$) (3). In obligately aerobic bacteria like *M. tuberculosis*, the generation of a PMF is mediated primarily by the proton-pumping components of the electron transport chain (Fig. 2, mechanism 3). As oxygen becomes limiting for growth, many bacterial pathogens switch to alternative electron acceptors (e.g., nitrate, fumarate), and proton release is

coupled to a terminal reductase (e.g., nitrate reductase) via a PMF redox loop mechanism (4) (Fig. 2, mechanism 2). *M. tuberculosis* harbors both nitrate reductase and fumarate reductase, but few direct experimental data have accumulated to suggest that they contribute to PMF generation under hypoxia. The membrane-bound F_1F_0 -ATP synthase can usually operate as a reversible ATP-driven proton pump to generate the PMF (5). However, in *M. tuberculosis* the enzyme shows extreme latency in the hydrolysis reaction (6). End-product (e.g., lactate) efflux can generate a PMF (7) (Fig. 2, mechanism 1), and it has been proposed that fumarate may be used as a mechanism to generate succinate as an excreted end product for maintenance of the membrane potential, under hypoxia, in *M. tuberculosis* (8).

A number of compounds target the PMF in bacteria (Fig. 3A), including agents that inhibit the major proton pumps (e.g., rotenone) and those that facilitate proton transport through the cytoplasmic membrane (protonophores, e.g., CCCP). The majority of protonophores are nonspecific and functional in both prokaryotic and eukaryotic cell membranes. Individual components of the PMF can be collapsed using specific

FIGURE 2 Mechanisms by which a proton motive (membrane potential [$\Delta\psi$] + transmembrane pH gradient [$Z\Delta\text{pH}$]) force can be generated in mycobacteria. **(1)** Cotransport of protons driven by solute (succinate) symport into the periplasm. **(2)** Redox-loop separation of charge; (mena)quinol oxidation results in proton release into the periplasm by virtue of (mena)quinol site proximity to the periplasm, while electrons are transferred to reduce a terminal electron acceptor (e.g., nitrate, fumarate) in the cytoplasm that results in neutralization of charge. **(3)** Proton translocation mediated by primary proton-pumping complexes (bc_1 - aa_3 supercomplex).

FIGURE 3 Traditional inhibitors of proton motive force generation. **(a)** Valinomycin is an ionophore, selective for potassium ions, which equilibrates the potassium gradient—dissipating the $\Delta\psi$ (electrogenic). Nigericin is a hydrophobic weak carboxylic acid which can traverse the membrane as its either protonated acid or neutral salt. It dissipates chemical gradients (i.e., ΔpH) but maintains the charge (one positive charge exchanged for one negative charge—electroneutral) (3). Carbonyl cyanide m-chlorophenyl hydrazone (CCCP) is an electrogenic protonophore. CCCP⁻ is driven to the periplasm by the $\Delta\psi$, while CCCP-H is driven to the cytoplasm by the ΔpH . It can equilibrate both $\Delta\psi$ and ΔpH . **(b)** Model for uncoupling by either pyrazinamide (PZA) or BDQ. (Left side) PZA diffuses into the cell and is converted to pyrazinoic acid (POA) by PncA (pyrazinamidase). Anionic POA could effectively inhibit growth through anion accumulation in the neutral pH of the cytoplasm and/or efflux from the cells to become protonated in the acidic extracellular environment (POA-H). POA-H would then diffuse back into the cell driven by the ΔpH gradient and dissociate in the cytoplasm (neutral pH), leading to intracellular acidification and cell death. (Right side) In a typical mycobacterial cell, the majority of ATP synthesis is respiratory, driven by the PMF. The binding of BDQ to the c-ring most likely perturbs the a-c subunit interface, causing an uncontrolled proton leak uncoupled from ATP synthesis and resulting in a futile proton cycle. Compensation by the exchange of other cations (i.e., K⁺) would allow the process to remain electroneutral.

inhibitors. For example, the membrane potential can be collapsed by compounds that catalyze electrogenic cation transport across the cell membrane (e.g., valinomycin) (Fig. 3a). Valinomycin is a dodecapeptide that forms a macrocyclic molecule allowing for rapid K⁺ movement down its electrochemical gradient. The chemical transmembrane gradient of protons (ΔpH) can

be collapsed by nigericin through its K⁺/H⁺ antiporter (electroneutral) activity (Fig. 3a). Growth of mycobacteria is sensitive to compounds that dissipate the membrane potential (e.g., protonophores and valinomycin), and these compounds are bactericidal toward growing and nongrowing (aerobic or hypoxic) cells, further highlighting the importance of the membrane

potential in mycobacterial viability (2, 3). Rao et al. (3) have reported that thioridazine, a compound purported to target NDH-2, results in dissipation of the $\Delta\psi$ and significant cell death. They suggested that NADH is an important electron donor for the generation of the $\Delta\psi$ under hypoxic conditions. Inhibitors of succinate dehydrogenase (SDH) (e.g., 3-propionate) are also able to dissipate the $\Delta\psi$ under hypoxia, suggesting that SDH is an important generator of the $\Delta\psi$ under hypoxia (9).

As the external pH of the growth medium changes and becomes mildly acidic, mycobacteria are able to generate a considerable transmembrane pH gradient (ΔpH) and maintain a constant PMF (2). While proton translocation via the respiratory chain generates the PMF, during respiration with oxygen as the terminal electron acceptor, it is not clear how the PMF is established in the absence of oxygen under microaerobic growth conditions. Anaerobic bacteria are able to generate a significant PMF (–100 mV) using their membrane-bound F_1F_0 -ATP synthase in the ATP hydrolysis direction (5). The ATPase activity (proton-pumping) of the enzyme is fueled by ATP produced by substrate-level phosphorylation. This mechanism does not appear to operate in mycobacterial cells where the F_1F_0 -ATP synthase has been reported to have latent ATPase activity when measured in inverted membrane vesicles (6, 10). Whether the enzyme is also latent in actively growing cells is not known, and therefore the potential does exist for this enzyme to function as a primary proton pump in the absence of oxygen and a functional respiratory chain to generate the PMF. The mechanisms controlling this extreme latency in the ATP hydrolysis direction are an area that could unlock new avenues for drug development and requires further investigation at a molecular and structural level.

The clinically approved antimycobacterial bedaquiline (Sirturo, TMC207) is a potent nanomolar inhibitor of the mycobacterial F_1F_0 -ATP synthase that binds to the enzyme's oligomeric c-ring to inhibit ATP synthesis (11–16). We have recently reported that bedaquiline activates respiration and is a potent uncoupler of respiration-driven ATP synthesis in mycobacteria (17). However, unlike classical uncouplers/protonophores, bedaquiline does not translocate protons *per se* but perturbs respiration by binding to F_0 (oligomeric c-ring) of the ATP synthase, likely disrupting the subunit a-c subunit interface in F_0 , thereby uncoupling proton flow from ATP synthesis by the F_1F_0 -ATP synthase (Fig. 3b). This uncoupling is electroneutral, consistent with no observed change in the membrane potential. Feng et al. (18) further demonstrated the potential of targeting the

PMF of *M. tuberculosis* and reported that a number of tuberculosis (TB) drugs (e.g., clofazimine, bedaquiline [BDQ], SQ109) are active uncouplers of the PMF in addition to binding to enzyme targets, highlighting the multitargeting nature of these molecules.

M. tuberculosis encounters acidic microenvironments in the host and must maintain its intracellular pH homeostasis to survive. Compounds that dissipate the transmembrane pH gradient lead to a rapid loss in cell viability at acidic pH and the lethal intracellular pH for mycobacterial species in the pH range of 5.5 to 6 (2). To address pH homeostasis as a drug target, Nathan and colleagues developed a whole-cell screen to identify compounds that dissipate the ΔpH gradient in *M. tuberculosis* (19). This study identified a number of candidate molecules, including PZA, that disrupted intracellular pH homeostasis and caused cell killing (loss of viability), highlighting this as a potential pathway for drug development (19) (Fig. 3b).

TARGETING PRIMARY DEHYDROGENASES IN *M. TUBERCULOSIS*: THE UNTAPPED SOURCE OF METABOLIC DRUG DISCOVERY

M. tuberculosis encodes several primary dehydrogenases that serve as direct reductants for electron transport (Fig. 1). Many of these have attractive properties for drug development, such as essentiality or lack of presence in the human genome. Unfortunately, the unifying feature of these enzymes is a paucity of information regarding their physiological and biochemical roles. Increasing our understanding of these processes will likely reveal mechanisms to perturb the viability within, and reactivation from, dormant mycobacteria.

NADH:Menaquinone Oxidoreductases

M. tuberculosis possesses two classes of NADH:menaquinone oxidoreductase to couple the oxidation of NADH from central metabolism to energize the electron transport chain (20) (Fig. 1). Like mitochondria, *M. tuberculosis* harbors a proton-pumping type I NADH dehydrogenase complex (NDH-1, complex I) that transfers electrons to menaquinone, conserving energy by translocating protons across the membrane to generate a PMF (Fig. 1 and Fig. 2). In *M. tuberculosis*, the *nuo* operon is not essential for either growth or persistence in an *in vitro* Wayne model (3). Moreover, the *nuo* operon has been lost from the genome of the intracellular parasite *Mycobacterium leprae* except for a single remaining *nuoN* pseudogene (21). These data suggest that NDH-1 does not represent a compelling

target for drug development. However, *M. tuberculosis* mutants lacking the NDH-1 subunit *nuoG* had reduced virulence in mice (22). There is evidence that *nuoG* and potentially other subunits of NDH-1 are antiapoptosis factors and are indeed potential candidates for vaccine development.

The second class of NADH:menaquinone oxidoreductase is the non-proton translocating type II NADH dehydrogenase (NDH-2) that does not conserve energy (Fig. 1). NDH-2 is a small monotopic membrane protein (50 to 60 kDa) that catalyzes electron transfer from NADH via FAD (noncovalently bound redox prosthetic group) to quinone. *M. tuberculosis* harbors two copies of NDH-2 (*ndh* Rv1854c and *ndhA* Rv0392c) (20), which are well conserved among slow-growing mycobacterial species. In *M. tuberculosis*, Ndh (1,392 bp) and NdhA (1,413 bp) share 65% identity, and the FAD- and NADH-binding motifs are highly conserved. The Ndh and NdhA proteins of *M. tuberculosis* have been shown to be functional NADH dehydrogenases that transfer electrons to the quinone pool via a two-site ping-pong reaction mechanism (23, 24). Several studies have suggested that *ndh* is essential for growth of *M. tuberculosis* (20, 25, 26), but the reasons for this essentiality remain unknown.

Unlike NDH-1, NDH-2 has not been reported in mammalian mitochondria, leading to the proposal that NDH-2 may represent a potential drug target for TB. Several antimycobacterial compounds have been reported to target NDH-2 (3, 20, 23, 27–30) (Fig. 4). For

example, drugs of the phenothiazine family (e.g., thioridazine, trifluoperazine, chlorpromazine) have potent activity *in vitro* against drug-susceptible and drug-resistant *M. tuberculosis* strains (31, 32) and show activity in a mouse model of pulmonary TB (20). However, the levels of phenothiazines required for antitubercular activity (>0.5 mg/liter of plasma) appear to be clinically unachievable in patients (33); the development of phenothiazines as antitubercular drugs is currently limited by the wide range of potentially serious off-target effects displayed during use, including cognitive effects in the central nervous system at concentrations lower than their antimycobacterial activity (34). In contrast to the phenothiazines, quinolinyl pyrimidines inhibit NDH-2 from *M. tuberculosis* in the nanomolar range and show no toxicity to the eukaryotic organism *Saccharomyces cerevisiae*, and no membrane disruption activity in a red blood cell hemolysis assay (30). The high potency and preliminary lack of toxicity against higher-order species are promising. Scopafungin, gramicidin S, and polymyxin B have been identified as inhibitors of *Mycobacterium smegmatis* NDH-2, and further work with *M. tuberculosis* is needed to determine their efficacy against the pathogen (35, 36).

Mode of action studies are required to understand how NDH-2 inhibitors work at a molecular and structural level and why inhibition of NDH-2 activity leads to cell death. Yano et al. (37) have shown that clofazimine (CFZ), a long-standing clinical drug for leprosy, is a redox-active (phenazine derivative) prodrug activated by

FIGURE 4 Inhibitors of the electron transport chain and F_1F_0 -ATP synthase of *M. tuberculosis*. Selected inhibitors of these complexes are indicated with flathead arrows and do not reflect the binding site of the inhibitors. Abbreviations: QPs, quinolinyl pyrimidines; TPZ, trifluoperazine; CFZ, clofazimine; 3-NP, 3-nitropropionate; SQ109, *N*-adamantan-2-yl-*N'*-((*E*)-3,7-dimethyl-octa-2,6-dienyl)-ethane-1,2-diamine; LPZ, lansoprazole; Q203, imidazopyridine amide; BDQ, bedaquiline.

NDH-2. The authors proposed a model in which the drug inhibits the growth of mycobacteria by a redox cycling pathway involving the enzymatic reduction of CFZ by NDH-2 followed by nonenzymatic reoxidation of CFZ by O₂, leading to the production of toxic reactive oxygen species (37). Hartkoorn et al. (38) reported that CFZ-resistant mutants of *M. tuberculosis* map to the transcriptional regulator *Rv0678*, leading to the up-regulation of the multisubstrate efflux pump, MmpL5. The authors showed that CFZ-resistant mutants are cross-resistant to bedaquiline, suggesting a common mechanism of resistance (38). In slow- and fast-growing mycobacterial species, reduction in NDH-2 activity has been linked to isoniazid and ethambutol resistance (39). Taken together, these studies suggest that the development of NDH-2 inhibitors will need to determine what effect these compounds have on current drug therapy regimens, particularly in regard to the development of cross-resistance.

Structure-aided drug design against NDH-2 is now possible with the first high-resolution bacterial structures published (40, 41). The bacterial NDH-2 structure reveals a homodimeric organization and localization to the cytoplasmic membrane by the membrane-anchoring domain highlighted with two amphipathic C-terminal helices (40, 41). Unique binding sites for quinone and NADH sites were also proposed, allowing concomitant oxidation of NADH from the cytoplasm with reduction of quinone from the membrane, with the ability of both substrates to access the FAD cofactor sequentially (40). This implies that NDH-2 harbors two potential drug target sites, and both warrant investigation. Most common structure-based drug design approaches rely on the protein-ligand complex structure model (42). The ligand-complex structures have been solved for both yeast (43) and bacterial NDH-2 (Y. Nakatani, unpublished data), allowing for the rational design of small inhibitor molecules targeting the NADH-binding site, and with further quinone-ligand structures, the quinone-binding site.

Succinate:Quinone Oxidoreductase: A Chink in the Carbon-Metabolic Armor

Succinate dehydrogenase (SDH), or complex II (Fig. 1), enzymes are well known for their role in the citric acid cycle. They couple the oxidation of succinate to the reduction of quinone via both FAD and heme cofactors (44), thereby playing important roles in both carbon metabolism and PMF generation. *M. tuberculosis* encodes two SDH enzymes (*sdh1*, *Rv0249c-Rv0247c*; *sdh2*, *Rv3316-Rv3319*), as well as a separate fumarate

reductase with possible bidirectional behavior. It is unprecedented in the current literature for an organism to encode three functionally redundant enzymes for this reaction, which complicates both physiological analysis and drug design. Furthermore, while a vast amount of literature exists regarding the SDHs of *Escherichia coli* and mitochondria, the SDHs encoded by mycobacteria have distinct phylogeny, prosthetic groups, and predicted biochemistry (9, 45). Despite these challenges, using SDHs as drug targets remains promising, because succinate is a major focal point in both the central carbon metabolism and respiratory chain of *M. tuberculosis*. The bacilli must find a way to drive the endergonic oxidation of succinate ($E_m = +113$ mV versus $E_m = -74$ for menaquinone): a reaction required for generating a membrane potential under hypoxia (9) and maintaining the balance of menaquinone:menaquinol (46). Under hypoxia, succinate can be electronically secreted or stored until a suitable electron acceptor is accessed (47). The versatility of succinate therefore suggests that disrupting its oxidation may result in clinically advantageous outcomes: inhibitors may have primary lethality, force a premature exit from nonreplicating persistence, or compromise bacilli reactivation, depending on which aspect of succinate metabolism is affected by modulating SDH activity.

Drug development targeting SDH enzymes will need to consider how to achieve selectivity for the multiple *M. tuberculosis* enzymes without off-target effects on human counterparts. Fortunately, several key differences between these homologues exist within the hydrophobic, menaquinone-binding portion of the complex. Enzymes are classified as types A to E according to their heme content and number of transmembrane subunits (45, 48). *Sdh2* is a type A enzyme (two subunits, two hemes) (49), while *Sdh1* was proposed to be similar to the *Bacillus*-like type B enzymes (one subunit, two hemes) (9). The mammalian SDH and *M. tuberculosis* fumarate reductase are of different types (types C and D, respectively), and thus are different in terms of electron transfer and menaquinone reduction. It follows that compounds targeting the hydrophobic subunits of SDH are ideally suited for achieving selective inhibition.

There have been no reported screens for inhibitors of mycobacterial SDH activity. A commonly used inhibitor of SDH is 3-nitropropionate, targeting the A subunit (50, 51), which has been reported to inhibit mycobacterial SDHs (9, 47). However, inhibitors developed against the dicarboxylate-binding site are likely to also inhibit mitochondrial SDH due to high A subunit similarity, and hence this is likely to be a poor direction

for lead candidate identification. Despite this, routine inhibitors such as the A subunit-targeting carboxin and quinone-mimic HQNO have been found to display selectivity between organisms (52), so this enzyme may yet serve as a lesson about the development of drugs against targets also present in mitochondrial genomes.

Alternative Dehydrogenases: Oxidative Phosphorylation Intrinsically Linked to Growth Reactivation

While mycobacteria are primarily heterotrophs, there is strong evidence that they can support chemolithotrophic growth on certain gases. *M. tuberculosis* is capable of supporting carboxydutrophic growth by utilizing carbon monoxide dehydrogenases (53) (CODH structural subunits, *Rv0375c-Rv0373c*) (Fig. 1). These enzymes oxidize CO to CO₂ concomitant with the reduction of various types of acceptors, ferredoxins, or cytochromes, for example (54, 55). The mycobacterial enzymes have additionally been proposed to oxidize NO (56). Aerobic CODHs are three-subunit enzymes that can be distinguished from their anaerobic counterparts by their molybdenum active sites (57, 58). They are typically induced under autotrophic conditions (59), although catabolite repression has been implicated in mycobacterial CODH regulation (60). Genetic essentiality has not been rigorously confirmed, although several transposon mutagenesis studies have putatively identified that the large subunit of CODH is essential (26, 61). The physiological electron acceptor of CODH has not been identified in mycobacteria, and doing so would likely reveal a more robust site for drug design, as opposed to targeting the gas-binding catalytic site.

While CO is abundant during host infection (62) and is likely an important energy source for the bacillus, the possibility of deleterious effects during CODH inhibition must be considered. CO and NO are inducers of the mycobacterial DosR response (63–65), both being apparent substrates of the mycobacterial CODH (56). As suggested previously (66), the metabolism of CO by CODH could serve as a reactivation signal by depleting the inducer. The potential metabolism of NO by CODH only further serves this hypothesis. It is therefore possible that inhibiting CODH will force a greater proportion of bacilli into a nonreplicating persistent state, by allowing accumulation of DosR inducers. Instead, CODH is a very promising target for activators, as opposed to inhibitors, because it could force these drug-resistant persisters to reactivate growth. This would allow the repurposing of classical antitubercular compounds in effective short-term regimens. Currently,

only molecules with broad-spectrum inhibitory activity, such as cyanide and derivative isonitriles, have been reported (67), and no activators have been reported at the time of writing.

Another potential respiratory electron donor in mycobacteria is F₄₂₀H₂. A low-potential two-electron carrier, F₄₂₀ plays a unique and central role in the redox metabolism of mycobacteria but is absent from human cells and gut microbiota (68). F₄₂₀ is reduced during central carbon catabolism of *M. tuberculosis* by an F₄₂₀-dependent glucose 6-phosphate dehydrogenase (69). Multiple F₄₂₀H₂-dependent reductases in turn couple the reoxidation of F₄₂₀H₂ to the reduction of diverse endogenous and exogenous heterocyclic organic compounds (68, 70, 71), among them quinones. It has been demonstrated that three such reductases of the split β -barrel family in *M. tuberculosis*, Rv3547, Rv1558, and Rv3178, can reduce quinone compounds through hydride transfer (72). It has been proposed that this activity maintains the quinone pool in a reduced state during oxidative stress (72); while rapid activity has been observed with nonphysiological quinones (72), it has yet to be confirmed if F₄₂₀H₂ oxidation can reduce menaquinone and generate PMF in whole cells. Irrespectively, mutants unable to synthesize or reduce F₄₂₀ are hypersusceptible to oxidative stress, antibiotic treatment, and hypoxia (72–74); hence, inhibitors of the F₄₂₀ system (including F₄₂₀ analogues) might selectively kill persistent mycobacteria and would act synergistically with first-line antimycobacterials. However, there may be even more promise in exploiting the mycobacterial FDORs to activate prodrugs. The 5-nitroimidazoles delamanid and pretomanid are reductively activated by Rv3547, resulting in production of reactive nitrogen species and *des*-nitro products that are proposed to kill *M. tuberculosis* through a combination of respiratory poisoning and inhibition of mycolic acid synthesis (71, 75–77). Delamanid is the second new drug in 40 years (following bedaquiline) to be clinically approved for TB treatment (78). Acquired resistance to delamanid in extensively drug-resistant TB has been reported to be mediated by mutations in *fbtA* (F₄₂₀ biosynthesis protein) and *fgd1* (F₄₂₀-dependent glucose-6-phosphate dehydrogenase) (79).

The enzymes discussed above demonstrate the potential array of treatment options that could be achieved with sufficient ingenuity. Valuable outcomes, such as direct lethality and modulation of growth state, can be hypothesized, and the potential to overcome undesirable target properties is readily apparent. NDH-2 has been extensively studied, and large high-throughput screens

for inhibitors performed with some success (20, 30, 80). Other primary dehydrogenases have received little attention. *M. tuberculosis* encodes far more primary dehydrogenases that are not covered here due to paucity of understanding in the context of mycobacterial oxidative phosphorylation. Most notably, there is a need to understand the role of the tricarboxylic acid cycle-linked malate:quinone oxidoreductase (Rv2852c) in the redox and ion homeostasis of *M. tuberculosis* (81, 82). Two quinone-linked glycerol-3-phosphate dehydrogenases (Rv3302c and Rv2249c) need to be dissected from a further two NAD(P)H-linked counterparts (Rv0564c and Rv2982c). In addition, the physiological conditions that would promote the activity of two L-lactate dehydrogenases (Rv0694 and Rv1872) need to be assessed, and it is not yet determined if quinone reduction by proline dehydrogenase occurs purely as a consequence of its previously demonstrated methylglyoxal-detoxification activity (83).

MENAQUINONE BIOSYNTHESIS: PROMISING DRUG TARGETS

Lipoquinones serve as the membrane-bound electron shuttles between primary dehydrogenases and terminal reductases in respiratory chains. Whereas ubiquinone serves as the predominant quinone in mitochondria and many Gram-negative bacteria, menaquinones are the predominant lipoquinones of mycobacteria and many other Gram-positive bacteria (84). It has recently been reported that polyketide-derived quinones are alternate lipoquinones that are expressed and function as electron carriers in mycobacterial biofilms (85). The biosynthesis of menaquinone requires two separate pathways (Fig. 5). 1,4-Dihydroxy-2-naphthoate is synthesized from chorismate. The naphthoate ring is then prenylated with a polyisoprenyldiphosphate, derived from isopentenyl diphosphate and dimethylallyl diphosphate, to form demethylmenaquinone, and subsequently, the C2 position of the ring structure is methylated. In mycobacteria the β -isoprene unit of the prenyl group is reduced to

form menaquinone-9 (II-H₂) after the formation of menaquinone (86). Menaquinone synthesis has been relatively extensively studied in *E. coli* (due in part to the availability of the *men* mutants, which can easily be generated in this organism, because it can utilize ubiquinone as an electron carrier in aerobic conditions). In *E. coli* the synthesis of menaquinone is accomplished by 10 enzymes (MenA–MenI and UbiE; see Fig. 5). These enzymes are encoded by two clusters of genes: the *men* cluster, consisting of *menB*, *C*, *D*, *E*, *F*, *H*, and a separate cluster containing *menA* and *ubiE*. It was originally thought that MenB catalyzed the conversion of 2-succinylbenzoyl-CoA to 1,4-dihydroxy-2-naphthoate; however, recent evidence indicates that MenB forms 1,4-dihydroxy-2-naphthoyl-CoA, which MenI then hydrolyzes to 1,4-dihydroxy-2-naphthoate (87).

Menaquinone synthesis in Gram-positive bacteria in general has largely been underrepresented in the literature; however, the general pathway in *M. tuberculosis* appears to be similar to that of *E. coli*. In *M. tuberculosis* the *menA–E* genes appear to be found in a single cluster along with the two genes annotated as possible methyl transferases involved in lipoquinone synthesis (Rv0558 and Rv0560c). One or both of these genes presumably encode the protein(s) (MenG, which has an analogous function to UbiE in *E. coli*) that methylate demethylmenaquinone. The gene encoding the protein with the most similarity to MenF in *E. coli* is Rv3215, annotated as *entC* (isochorismate synthase), and the gene encoding the protein most similar to MenI in *E. coli* is Rv1847. In addition, *M. tuberculosis* harbors Rv0561c, which is clustered with *menA–E* and encodes MenJ, the enzyme that reduces the β -isoprene of menaquinone (86). Interestingly, *M. tuberculosis* does not have a gene that is easily identifiable as encoding a protein with similar function to MenH. Rv0045c, Rv1938, and Rv2715 are all potential candidates, although none encode a protein with a high degree of similarity to MenH from *E. coli*. The isoprenoid tail of the menaquinone must be generated by an isoprenyl diphosphate synthase as described above, and together with 1,4-dihydroxy-2-naphthoic acid these

FIGURE 5 Proposed menaquinone biosynthesis pathway in mycobacteria based on the known pathway in *E. coli*. In this scheme the product of MenA is depicted as the quinone rather than the quinol. This is consistent with the majority of the menaquinone literature (167), which indicates that the oxidation from quinol to quinone is spontaneous but differs from ubiquinone synthesis. The arrows indicate C2 and C3 of menaquinone-9(II-H₂). Abbreviations: DHNA, 1,4-dihydroxy-2-naphthoate; DHNA-CoA, 1,4-dihydroxy-2-naphthoyl-CoA; OSB, o-succinylbenzoate; OSB-CoA, o-succinylbenzoyl-CoA; SEPHCHC, 2-succinyl-5-enolpyruvyl-6-hydroxy-3-cyclohexadiene-1-carboxylate; SHCHC, 2-succinyl-6-hydroxy-2,4-cyclohexadiene-1-carboxylate.

are the substrates for MenA (Rv0534c). However, the specific synthase generating this isoprenyl diphosphate has yet to be identified.

Surprisingly, not all of the enzymes involved in the mycobacterial menaquinone biosynthetic pathway appear to be viable drug targets, or even essential. Initial studies (25) predicted that the mycobacterial *menC*, *menD*, *menE*, and *menF* genes were essential for bacterial survival. Subsequently, these predictions were supported by high-resolution phenotypic profiling experiments (26), which added *menF* and *menA* to the list of predicted essential genes. MenA (demethylmenaquinone synthase, Rv0534c [88, 89]), MenB (1,4-dihydroxy-2-naphthoyl-CoA synthase, Rv0548c [20–22]), and MenE (*o*-succinylbenzoyl-CoA synthase, Rv0542c [90–92]) from mycobacteria are being studied as potential drug targets, having been genetically or pharmacologically demonstrated to be essential. This is exemplified by the development of aurachin RE analogues, which inhibit MenA and result in growth inhibition of drug-resistant *M. tuberculosis* (89). It seems probable that MenC, D, and F are potential drug targets in addition to MenA, B, and E. MenG has yet to be definitively identified in mycobacteria. As noted above, two genes are annotated as possible methyl transferases involved in lipoquinone synthesis (*Rv0558* and *Rv0560c*). Both of these genes reside in the Men cluster in *M. tuberculosis*; however, only *Rv0558* is predicted to be essential (25, 26, 93). Thus, further study is indicated.

MenI has only recently been identified as the enzyme that hydrolyzes 1,4-dihydroxy-2-naphthoyl-CoA to 1,4-dihydroxy-2-naphthoate in *E. coli* (87). An orthologous gene has not been positively identified in mycobacteria, although *Rv1847* appears to be the highest probability match. This gene is predicted to be nonessential for mycobacterial survival (25, 26, 93). This is perhaps unremarkable because deletion of MenI in *E. coli* does not eliminate menaquinone synthesis; it only reduces the levels of menaquinone in the bacteria by 67% (87), suggesting that other nonspecific thioesterase activities can compensate. Similarly *Rv0045c*, *Rv1938*, and *Rv2715* encode potential, but low probability, candidates for 2-succinyl-6-hydroxy-2,4-cyclohexadiene-1-carboxylate synthase (MenH) in *M. tuberculosis*, none of which are predicted to be essential. It should be noted that 2-succinyl-5-enolpyruvyl-6-hydroxy-3-cyclohexadiene-1-carboxylate can undergo spontaneous elimination to form 2-succinyl-6-hydroxy-2,4-cyclohexadiene-1-carboxylate (94). Thus, mycobacterial MenI and MenH do not appear to be likely drug targets. MenJ is unique among the *men* genes in that it is

nonessential for growth in culture (25, 26, 86) but is essential for bacterial survival in mouse macrophages (86, 95). Thus, menaquinone with partially saturated isoprenyl moieties appears to be a novel virulence factor, and MenJ is a contextually essential enzyme and a potential drug target (86). Sulfated menaquinone synthesis does not appear to present an important drug target. The function of this unique lipid is, as yet, unknown; however, it has been reported that the synthesis of sulfated menaquinone reduces the virulence of the organism in mouse infection models (96).

TARGETING OXYGEN REDUCTION IN MYCOBACTERIA

All mycobacteria sequenced to date harbor genes for a cytochrome *c* pathway consisting of a cytochrome *bc*₁ (related to the mitochondrial complex III) and an *aa*₃-type cytochrome *c* oxidase (complex IV) (Fig. 1). The cytochrome *bc*₁ transfers electrons from menaquinol to the cytochrome *c* oxidase, a process linked to proton translocation across the membrane. Since the cytochrome *c* oxidase is also capable of pumping protons, this pathway is the most energetically favorable respiratory branch in mycobacteria. In contrast to mitochondria, actinobacteria do not possess genes for soluble cytochrome *c* or any other *c*-type cytochrome (97, 98). Instead, the complexes III and IV form a supercomplex that facilitates the direct transfer of electrons from menaquinol to oxygen (98–100). The *bc*₁ complex (encoded by the *qcrCAB* operon) is composed of the cytochrome *b* (*qcrB*), which contains two *b*-type heme groups, a 2Fe-2S iron-sulfur cluster located on the Riske protein QcrA, and a di-heme *c*-type cytochrome *c*₁ (*qcrC*), as initially described in *Corynebacterium glutamicum* (101).

The *aa*₃-type cytochrome *c* oxidase is encoded by the *ctaB*, *ctaC*, *ctaD*, and *ctaE* genes. The genes *ctaD* and *ctaC* are in close proximity to the *qcrCAB* operon, whereas *ctaB* and *ctaE* are located elsewhere in the genome. The cytochrome *c* oxidase contains three redox centers: CuA (located on CtaC, subunit II) and the heme *a* (located on CtaD, subunit I) are the primary electron acceptors from the *bc*₁ complex, whereas the *a*₃-CuB unit (located on CtaD) is the oxygen-reducing element. The cytochrome *c* oxidase is annotated as essential (25), whereas attempts to delete *qcrCAB* in *M. tuberculosis* were unsuccessful (102), suggesting that the cytochrome *c* pathway is required for the survival of slow-growing mycobacteria. *qcrCAB* could be deleted in *M. smegmatis* but led to a profound growth impairment *in vitro*

(102). Recently, the thioredoxin CcsX was shown to be required for heme insertion into membrane-bound heme-containing proteins (103). Deletion of *ccsX* in *M. tuberculosis* had a marked growth defect due to a deficient heme insertion in membrane-proteins, including QcrC. Nevertheless, the mutant strain could still multiply (103), suggesting that the perturbation, or inactivation, of the cytochrome *c* branch may be viable under certain circumstances. Interestingly, the cytochrome *bd* oxidase was upregulated in the *ccsX* mutant strain, suggesting that the cytochrome *bd* oxidase can act as a robust alternate terminal oxidase when the integrity of the cytochrome *c* branch is compromised (103).

Several inhibitors of the cytochrome *bc*₁ are known. The archetype is stigmatellin, a natural antibiotic that inhibits most cytochrome *bc*₁ by impeding the interaction of the quinol with the QcrB subunit. The recent discovery of small molecules targeting QcrB has triggered interest in the respiratory cytochrome *c* pathway (104–107). A number of groups have identified a series of imidazopyridine amide (IPA) compounds that interfere with energy metabolism (104–106, 108). The most advanced derivatives of the IPA series are active in the low nanomolar range *in vitro* (106, 108, 109). The series is surprisingly highly selective to mycobacteria since it does not inhibit the growth of any other bacteria or microorganism classes that were tested (104, 106). Whole-genome sequencing of spontaneous-resistant mutants to the IPA drugs revealed that a single amino acid substitution at position 313 in QcrB confers high resistance to Q203 (104, 106). Subsequently, additional mutations were identified in a strain deficient for the expression of the cytochrome *bd* oxidase (105). Since all the mutations conferring resistance are in close proximity to the Qp menaquinone-binding site, it is likely that the IPA compounds inhibit respiration by interfering with the binding of menaquinol at the Qp site of QcrB. Even though target engagement remains to be demonstrated, the observation that the IPA series triggers a rapid ATP depletion (105, 106) suggests that the cytochrome *bc*₁ is the direct target. The drug candidate Q203 recently progressed to clinical development phase I under a U.S. FDA investigational new drug application, marking the first step to validate the vulnerability of the cytochrome *c* pathway in human TB.

Several other compound series targeting QcrB have been reported (105, 107), arguing for a high level of vulnerability of this respiratory branch under conditions used for compound screening. Of particular interest, the approved drug lansoprazole is a prodrug targeting QcrB in mycobacteria (107). Despite the high vulnerability

of the cytochrome *bc*₁, it is puzzling to note that all the inhibitors discovered to date bind to a narrow region of the QcrB subunit that is predicted to interact with menaquinol. A better understanding of the biology of the cytochrome *c* branch may allow for the identification of lead molecules that bind to alternate positions. Although exciting drug development advances have been made, much work remains to be done to understand the biology of cytochrome *bc*₁ and under which conditions the cytochrome *c* branch is essential for survival. As such, it was observed that the high expression of the cytochrome *bd*-type oxidase in laboratory strains of *M. tuberculosis* can partly alleviate the potency of cytochrome *bc*₁ inhibitors (105). Although this was not the case for clinical isolates that seem to regulate cytochrome *bd* expression more tightly (105), it is imperative to clarify the synthetic genetic interaction between the two terminal oxidases to exploit the full potential of QcrB inhibitors for the treatment of TB. Furthermore, the conditions under which alternate terminal acceptors can compensate for the inhibition of the *bc*₁ complex must also be delineated to develop a rational drug combination targeting oxidative phosphorylation. It is interesting to note that ongoing reductive evolution in *M. leprae* and *Mycobacterium ulcerans* resulted in the deletion of the cytochrome *bd* oxidase, nitrate reductase, and fumarate reductase (21, 110), leaving the cytochrome *c* oxidase branch as the only functional terminal electron acceptor. Therefore, drugs targeting cytochrome *bc*₁ hold great promise for the treatment of leprosy and Buruli ulcer infections.

Cytochrome *bd*-Type Oxidase and CydDC

M. tuberculosis and other mycobacterial species harbor genes for the cytochrome *bd*-type menaquinol oxidase (*cydAB*) (111) (Fig. 1). Cytochrome *bd* oxidase (CbdO) could be viewed as one of the most scientifically neglected and least understood respiratory enzymes in the electron transport chain of *M. tuberculosis*. The rather modest interest in this *M. tuberculosis* enzyme might stem from its dispensability for optimal growth and survival in mouse models (25, 61). In the absence of structural or biochemical data for CbdO of *M. tuberculosis*, it is assumed that this enzyme functions similarly to its well-characterized *E. coli* homologue as a high-affinity terminal oxidase that accepts electrons from menaquinol to reduce oxygen under hypoxic conditions (112–114). This enzyme activity contributes to the maintenance of a PMF and facilitates the scavenging of oxygen necessary to colonize oxygen-poor niches or to protect oxygen-labile enzymes (112, 114–116). From an

energetic point of view, cytochrome *bd* oxidase is less efficient than cytochrome *c* oxidases because it does not pump protons but instead generates a PMF by transmembrane charge separation at an H^+/e ratio of 1 (113). This would appear useful for cells under conditions where the role of CbdO is not primarily to create a PMF, but to serve as an electron sink, for example, during reductive, oxidative, or nitrosative stress defenses (117) or during disulfide-bond formation (114).

Downstream of the *cydAB* gene locus of *M. tuberculosis*, another operon, *cydDC*, encodes a putative ABC-transporter. In *E. coli* this transporter was shown to transport glutathione and cysteine to the periplasm, where these molecules contribute to redox homeostasis and disulfide bond formation (114). Similar to CbdO, CydDC of *M. tuberculosis* is largely uncharacterized, and its physiological role is unclear. Mouse infection studies with transposon mutant libraries indicate that mutants with insertions in CydDC are at a disadvantage compared to the wild-type cells (118). However, mouse challenge with single *cydC* mutants shows no growth attenuation and only a subtle decrease in bacillary loads in lungs during latent infection (119), although a subsequent study was unable to reproduce this phenotype (120). It is important to note that mice do not form hypoxic granulomas, which could explain why neither *cydAB* nor *cydDC* mutants are attenuated in this animal model.

Cytochrome *bd* oxidase and the CydDC transporter appear to protect mycobacteria from chemotherapeutic challenge. For example, disruption of *cydC* in *M. tuberculosis* caused increased bacterial clearance in mouse model infections treated with isoniazid when compared to wild-type infections (120). An even more striking observation has been the role of CbdO, specifically in protection of *M. tuberculosis* from respiratory chain inhibitors. Berney et al. demonstrated that *cydA* deletion greatly enhances the early bactericidal activity (eBA), killing in the first 7 days, in *M. tuberculosis* treated with the F_1F_0 -ATP synthase inhibitor bedaquiline (121). In another study, *cydA* inactivation in *M. tuberculosis* H37Rv enhanced the MIC of cytochrome *c* oxidoreductase inhibitors by more than 4 orders of magnitude (105). Consistent with these data, deletion of *cydA* in *M. smegmatis* greatly decreased the MIC of bedaquiline (17) and led to complete sterilization after clofazimine treatment for 72 hours, while effects on the wild-type and the cytochrome *bc₁* mutant were only bacteriostatic (122). However, the mechanism of action of this phenotypic resistance and the more pronounced role in protection from respiratory chain inhibitors is unclear.

CbdO and CydDC enzymes also appear important in adaptation to adverse conditions and persistence. Kana et al. showed that inactivation of *cydA* in *M. smegmatis* inhibits cell growth under hypoxic conditions (111). It is intriguing to note that inactivation of the cytochrome *c* maturation pathway in *M. tuberculosis* led to upregulation of CbdO concomitant with increased resistance to hydrogen peroxide (103). Accordingly, *cydA* deletion in *M. smegmatis* (122) and *M. tuberculosis* (M. Berney, unpublished results) increases susceptibility to peroxide. Taken together with the observed protection from antibiotics, this can lead one to assume that cytochrome *bd* oxidase and potentially CydDC are important in pathogenicity and adaptation to adverse conditions. Interestingly, *cydAB* and *cydDC* are upregulated as part of hypoxia-induced dormancy (123) and may facilitate *M. tuberculosis* transition to nonreplicating persistence (124). Bacilli in this state are tolerant to antibiotics (125, 126), and it is possible that the phenotypic resistance to drugs is due in part to a CbdO-facilitated transition to persistence.

Neither cytochrome *bd* oxidase nor the CydDC transporter appears to be essential for the survival or normal growth of *M. tuberculosis* under standard conditions. However, their unique roles discussed above and the lack of mammalian homologues warrant their investigation as potential drug targets. When *M. tuberculosis* is treated with bedaquiline, the dormancy regulon and ATP-generating pathways, including *cydAB* and *cydDC* genes, are activated and induce metabolic remodeling that delays bactericidal activity (127). As noted, inactivation of CbdO inhibits this phenotypic resistance and promotes *de novo* early bactericidal activity of BDQ (121). It is possible that similar mechanisms of resistance are employed in response to a broad range of chemotherapeutics (128). Furthermore, CbdO is likely the predominant terminal oxidase under low oxygen tensions (111, 119, 129) such as those found in hypoxic granulomas (130) and may facilitate the survival of latent or persistent bacilli (131, 132). Therefore, it is conceivable that inhibitors of CbdO or CydDC would enhance the eBA of existing chemotherapeutics and target nonreplicating bacilli populations, which could effectively reduce the currently lengthy therapy timelines (133).

The only cytochrome *bd* oxidase-selective inhibitors currently identified are aurachin D and its analogues (134). Aurachin D is a quinolone-type drug that prevents menaquinol reduction (134) by competitive inhibition at the quinol-binding domain of CbdO (135). Its selective inhibition of CbdO has been validated in

M. smegmatis by measuring oxygen consumption of membrane vesicles (122). Its efficacy as a chemotherapeutic and toxicity to mammals have not been studied. To our knowledge, no inhibitors of the CydDC transporter have been identified. This general lack of development is likely because inhibitors of these enzymes are not a promising source of stand-alone drugs for treatment of *M. tuberculosis* under aerobic conditions. However, the attributes of CbdO and CydDC discussed here suggest that they may be valuable drug targets to enhance the efficacy and reduce the treatment timelines of current chemotherapy regimens.

Alternative Reductases: Critical for Redox Homeostasis during Hypoxia

There is strong evidence that *M. tuberculosis* uses the alternative electron sinks nitrate, nitrite, and fumarate to maintain redox balance during hypoxia. *M. tuberculosis* exploits host defenses to generate the respiratory electron acceptor nitrate. The organism converts the nitric oxide (NO) produced by host inducible NO synthase (iNOS) in the human macrophage to nitrate by secreting the nitric oxide dioxygenase HbN (136, 137). It in turn imports the nitrate produced with a specific transporter (NarK2), reduces nitrate to nitrite with a membrane-bound respiratory nitrate reductase (NarGHJI), and detoxifies the nitrite to ammonium with a cytosolic NADH-dependent nitrite reductase (NirBD) (138, 139). While nitrate reductase and nitrite reductase are constitutively expressed, the nitrate transporter is under tight transcriptional control by the NO- and hypoxia-induced DosS/DosT-DosR system (119, 140, 141), and hence the rate of nitrate reduction increases in hypoxic cells concurrent with reduction of the respiratory chain (139). While the physiological role of this pathway is incompletely understood, it appears to enhance the flexibility of mycobacteria in response to reductive stress: nitrate supplementation enhances the survival of *M. tuberculosis* cultures following sudden anaerobiosis or phenothiazine treatment (142, 143). The nitrite produced can be exported from the cell or alternatively reduced to ammonium; the nitrite reductase that mediates this process is essential for survival of *M. tuberculosis* both in the Wayne model and in human macrophages, likely due to its combined roles in nitrite detoxification and nitrogen assimilation (138, 144, 145). Given the multifaceted roles of nitrate and nitrite reduction in this pathogen, there may be potential in developing small-molecule inhibitors of nitrate reductase and nitrite reductase. Host-directed therapies aimed at reducing NO production also show promise (146), though

they could also be counterproductive given that NO also has innate cytotoxic effects: administration of the iNOS2 inhibitor N^6 -(1-iminoethyl)-L-lysine accelerated progress of *M. tuberculosis* infection in a murine model (147).

There is also a weight of evidence that *M. tuberculosis* depends on fumarate reduction to adapt to hypoxia. Two groups have independently demonstrated that *M. tuberculosis* operates a reverse tricarboxylic acid cycle during hypoxia, resulting in fumarate production and succinate excretion (8, 47). Given that succinate is a multifunctional molecule, this remodeling may serve several purposes: (i) respiratory electron transport to fumarate generates PMF by a redox-loop mechanism, (ii) fermentative succinate excretion to the extracellular milieu dissipates excess reductant, and (iii) succinate may be used for anaplerosis or respiration according to cellular needs (8, 47). In contrast to its saprophytic relatives, *M. tuberculosis* has acquired a canonical fumarate reductase that likely mediates the majority of these activities. There is evidence that the two aforementioned annotated succinate dehydrogenases in its genome (Sdh1, Sdh2) can operate in a reversed direction to compensate for loss of this enzyme (8, 9, 46, 47). Consistent with such roles, both the canonical fumarate reductase and Sdh2 are strongly upregulated and highly active under hypoxia (8, 9, 46, 148). Given this functional redundancy, genes encoding these enzymes can be individually but not collectively deleted (8, 9, 47), and hence it may be difficult to develop effective inhibitors against the fumarate reduction pathway. However, an exciting precedent has been set by the discovery of nanomolar affinity natural products (e.g., nafured, verticipyron) that inhibit eukaryotic parasites by targeting mitochondrial fumarate reductases (149). The finding that succinate may be excreted as a fermentative end-product in mycobacteria is also worthy of special attention (8). Other recent work has suggested that, while mycobacteria strictly require respiration for growth, they may resort to fermentation if all respiratory electron acceptors are exhausted (150). It is important to gain a further understanding of the electron sinks that *M. tuberculosis* uses to maintain redox balance in order to evaluate current and discover new drug targets in mycobacterial energetics.

ATP SYNTHESIS BY THE F_1F_0 ATP SYNTHASE: A CLINICALLY VALIDATED TARGET

In *M. tuberculosis* and other mycobacterial species, ATP is synthesized via substrate-level phosphorylation and oxidative phosphorylation using the membrane-bound

F_1F_0 -ATP synthases (encoded by the *atpBEFHAGDC* operon, Rv1304-1311). The F_1F_0 -ATP synthase catalyzes ATP synthesis by utilizing the electrochemical gradient of protons to generate ATP from ADP and inorganic phosphate (P_i) and operates under conditions of a high PMF and low intracellular ATP. The enzyme is also capable of working as an ATPase under conditions of high intracellular ATP and an overall low PMF (151). As an ATPase, the enzyme hydrolyzes ATP while pumping protons from the cytoplasm to the outside of the cell. The ATP synthase of mycobacteria has been studied in detail at a biochemical level in *M. phlei* and shown to exhibit latent ATPase activity (10). ATPase activity could be activated by trypsin treatment and magnesium ions, but the mechanism of activation was not elucidated. Recent experiments with inverted membrane vesicles of *Mycobacterium bovis* BCG and *M. smegmatis* demonstrate latent ATPase activity that could be activated by methanol and the PMF, suggesting regulation by the epsilon subunit and ADP inhibition (6). The reason for the extreme latency in ATP hydrolysis of the mycobacterial ATP synthase is unknown but may represent an adaptation to function at low PMF and under hypoxia. Hypoxic nonreplicating cells of *M. tuberculosis* generate a PMF on the order of -100 mV, and the ATP synthase inhibitor TMC207 is bactericidal toward these cells, demonstrating that the ATP synthase still continues to function at relatively low PMF (3).

The F_1F_0 -ATP synthase in *M. tuberculosis* and *M. smegmatis* has been shown to be essential for optimal growth (25, 152). In other bacteria, the F_1F_0 -ATP synthase is dispensable for growth on fermentable carbon sources (153, 154), where increased glycolytic flux can compensate for the loss of oxidative phosphorylation. This strategy does not appear to be exploited by *M. smegmatis*: the F_1F_0 -ATP synthase is essential for growth even on fermentable substrates, suggesting that ATP production from substrate-level phosphorylation alone, despite increased glycolytic flux, may be insufficient to sustain growth of these bacteria (152). This may be due to an extraordinarily high value for the amount of ATP required to synthesize a mycobacterial cell, a possibility that requires further investigation (155). Alternatively, in conjunction with a high ATP demand for growth, the ATP synthase may be an obligatory requirement for the oxidation of NADH by providing a sink for translocated protons during NADH oxidation coupled to oxygen reduction (152). Such strict coupling would imply that mycobacteria do not support uncoupled respiration; either they lack a conduit for proton re-entry in the absence of the F_1F_0 -ATP synthase or they

are unable to adjust the proton permeability of the cytoplasmic membrane to allow a futile cycle of protons to operate. In this context, the cytoplasmic membrane of *M. smegmatis* has been shown to be extremely impermeable to protons (156). In *M. tuberculosis*, the *atp* operon is downregulated during growth in macrophages (157), in the mouse lung, and in cells exposed to NO or hypoxia (119). The *atp* operon of *M. bovis* BCG and *M. smegmatis* is downregulated in response to slow growth rate (158, 159). When slow-growing cells of *M. smegmatis* (70 h doubling time) with low levels of *atp* operon expression are exposed to hypoxia (0.6% oxygen saturation), the *atp* operon is upregulated 3-fold, suggesting an important role for this enzyme during adaptation to hypoxia (158).

Several new antitubercular compounds have been reported that target oxidative phosphorylation in mycobacteria (11, 20, 88). The most promising compounds clinically, the diarylquinolines, have been shown to target the F_1F_0 -ATP synthase and inhibit ATP synthesis (11–13). The FDA approved the use of a diarylquinoline (i.e., first-in-class compound BDQ) for treatment of multidrug-resistant TB in 2012, which was the first drug licensed in 40 years for TB disease. BDQ was developed in an attempt to improve outcomes in multidrug-resistant TB patients due to the suboptimal effectiveness and toxicity of currently available drugs and regimens. BDQ has fast-acting bactericidal *in vivo* activity in different animal models and in TB patients against several mycobacterial species, both susceptible and resistant to all first-line and many second-line drugs (160, 161). However, resistance to BDQ has already been reported (127), and phase 2 clinical trials showed a higher mortality rate in subjects assigned to the bedaquiline cohort compared to the placebo group (162). Additionally, BDQ accumulates in tissues and has a prolonged half-life, taking 8 weeks to reach peak exposure and displaying a terminal half-life of 4 to 5 months.

Genome sequencing of both *M. tuberculosis* and *M. smegmatis* mutants that are resistant to diarylquinolines (i.e., TMC207) revealed that the target of these compounds is the oligomeric c-ring (encoded by *atpE*) of the enzyme (11, 14, 15). The high-resolution X-ray structure of the oligomeric c-ring of *M. phlei* has been solved complexed with BDQ. The structure reveals that BDQ interacts with the oligomeric c-ring via numerous interactions (hydrophobic, hydrophilic, and electrostatic) completely covering the c-ring's proton-binding sites, thus explaining the high-affinity (nM) binding of BDQ to the *M. phlei* c-ring and the measured low MIC values of BDQ toward *M. tuberculosis* (11). The binding

of BDQ to the c-ring prevents the rotor ring from acting as a proton shuttle and stalls ATP synthase operation (16). The structures explain how diarylquinolines specifically inhibit the mycobacterial ATP synthase and thus will enable structure-based drug design for next-generation ATP synthase inhibitors against *M. tuberculosis* (16, 163, 164).

When mycobacterial cells (growing or nongrowing) are treated with BDQ, time-dependent (not dose-dependent) killing is observed (11, 127). The mechanism of killing is not clear but does not involve the dissipation of the membrane potential, which is lethal to all living cells. A dose-dependent decrease in intracellular ATP has been observed when *M. tuberculosis* cells are treated with TMC207 (12, 13), but these data do not explain cell death because mycobacterial cells can be depleted of ATP and yet remain viable (165). We have shown that BDQ kills nonreplicating mycobacterial cells by a unique mechanism that involves uncoupling of the electron transport chain (through ATP synthase), leading to a futile cycling of protons that causes cell death (17). A striking observation during this work was the activation of respiration by BDQ, suggesting a protonophoric-like activity. As discussed above, this was due to binding the *c* subunit of the F_0 subunit.

A NEED TO UNDERSTAND ENERGETIC PLASTICITY AND ANTIMICROBIAL RESISTANCE/SUSCEPTIBILITY

The energetic targets discussed in this chapter play essential roles in mycobacterial metabolism and respiration under different host conditions. There is a need for continued fundamental research to clarify the molecular interactions and compensatory expression between various energetic targets to develop a rational drug combination targeting oxidative phosphorylation. The discovery of bedaquiline demonstrates that energetic targets provide a pathway to discover fast-acting drugs that eradicate replicating and nonreplicating cells. The mode of bedaquiline action further highlights the multitargeting nature of these molecules. The promise of respiration and oxidative phosphorylation as a new target space is highlighted by the discovery that bacterial respiration is essential for the killing of *E. coli* by ampicillin, gentamicin, and norfloxacin (166). In *E. coli*, cytochrome *bo* and cytochrome *bd* mutants are resistant to the killing effects of ampicillin, gentamicin, and norfloxacin (166). In contrast to *E. coli*, cytochrome *bd* mutants of *M. tuberculosis* (121) and *M. smegmatis* (17, 122) become hypersusceptible to bedaquiline, clofazi-

mine, and hydrogen peroxide (17, 121, 122). These data suggest that the inhibitors of cytochrome *bd* would indeed be synergistic with bedaquiline and clofazimine, making this a priority target for inhibitor discovery.

When *M. tuberculosis* is grown in aerobic batch culture, the rate of oxygen consumption is precisely regulated as a function of percentage air saturation (46). Under these conditions, cells are able to direct electron flow to both terminal respiratory oxidases (cytochrome *bd* and *aa₃*-type cytochrome *c* oxidase), allowing the cell to rapidly adjust to changes in the PMF and direct electrons to the appropriate oxidase (proton pumping or non-proton pumping) in response to physiological demand (17, 122). The mechanisms that control the rate of oxygen consumption by *M. tuberculosis* are not known. Succinate dehydrogenase and NADH dehydrogenase mutants of *M. tuberculosis* are perturbed in oxygen management, leading to higher rates of oxygen consumption during normal growth and a survival defect in stationary phase (46). These data suggest that the identification of molecules that activate respiration in *M. tuberculosis* may be effective in killing nonreplicating cells and synergizing with current TB drugs. The scope that exists for modulating TB metabolism sets the scene for several exciting innovations and discoveries, a promising contrast to other targets that may soon reach the point of saturation.

ACKNOWLEDGMENTS

Research in the authors' laboratory is funded by Health Research Council, Lottery Health, Marsden Fund, Royal Society New Zealand, and the Maurice Wilkins Centre. D.C.C. acknowledges the support of NIH/NIAID grant AI049151. M.B. was supported by NIH grant R21AI119573.

REFERENCES

1. Brodie AF, Gutnik DL (ed). 1972. *Electron Transport and Oxidative Phosphorylation in Microbial Systems*. Marcel Dekker Inc., New York, NY.
2. Rao M, Streur TL, Aldwell FE, Cook GM. 2001. Intracellular pH regulation by *Mycobacterium smegmatis* and *Mycobacterium bovis* BCG. *Microbiology* 147:1017–1024 <http://dx.doi.org/10.1099/00221287-147-4-1017>.
3. Rao SP, Alonso S, Rand L, Dick T, Pethe K. 2008. The protonmotive force is required for maintaining ATP homeostasis and viability of hypoxic, nonreplicating *Mycobacterium tuberculosis*. *Proc Natl Acad Sci USA* 105:11945–11950 <http://dx.doi.org/10.1073/pnas.0711697105>.
4. Jormakka M, Byrne B, Iwata S. 2003. Protonmotive force generation by a redox loop mechanism. *FEBS Lett* 545:25–30 [http://dx.doi.org/10.1016/S0014-5793\(03\)00389-2](http://dx.doi.org/10.1016/S0014-5793(03)00389-2).
5. Dimroth P, Cook GM. 2004. Bacterial Na⁺- or H⁺-coupled ATP synthases operating at low electrochemical potential. *Adv Microb Physiol* 49:175–218 [http://dx.doi.org/10.1016/S0065-2911\(04\)9004-3](http://dx.doi.org/10.1016/S0065-2911(04)9004-3).
6. Haagsma AC, Driessen NN, Hahn MM, Lill H, Bald D. 2010. ATP synthase in slow- and fast-growing mycobacteria is active in ATP synthesis and blocked in ATP hydrolysis direction. *FEMS Microbiol Lett* 313:68–74 <http://dx.doi.org/10.1111/j.1574-6968.2010.02123.x>.

7. Otto R, Sonnenberg AS, Veldkamp H, Konings WN. 1980. Generation of an electrochemical proton gradient in *Streptococcus cremoris* by lactate efflux. *Proc Natl Acad Sci USA* 77:5502–5506 <http://dx.doi.org/10.1073/pnas.77.9.5502>.
8. Watanabe S, Zimmermann M, Goodwin MB, Sauer U, Barry CE III, Boshoff HI. 2011. Fumarate reductase activity maintains an energized membrane in anaerobic *Mycobacterium tuberculosis*. *PLoS Pathog* 7:e1002287 <http://dx.doi.org/10.1371/journal.ppat.1002287>.
9. Peci I, Hards K, Ekanayaka N, Berney M, Hartman T, Jacobs WR Jr, Cook GM. 2014. Essentiality of succinate dehydrogenase in *Mycobacterium smegmatis* and its role in the generation of the membrane potential under hypoxia. *MBio* 5:e01093-14 <http://dx.doi.org/10.1128/mBio.01093-14>.
10. Higashi T, Kalra VK, Lee SH, Bogin E, Brodie AF. 1975. Energy-transducing membrane-bound coupling factor-ATPase from *Mycobacterium phlei*. I. Purification, homogeneity, and properties. *J Biol Chem* 250:6541–6548.
11. Andries K, Verhasselt P, Guillemont J, Göhlmann HW, Neefs JM, Winkler H, Van Gestel J, Timmerman P, Zhu M, Lee E, Williams P, de Chaffoy D, Huitric E, Hoffner S, Cambau E, Truffot-Pernot C, Lounis N, Jarlier V. 2005. A diarylquinoline drug active on the ATP synthase of *Mycobacterium tuberculosis*. *Science* 307:223–227 <http://dx.doi.org/10.1126/science.1106753>.
12. Koul A, Dendouga N, Vergauwen K, Molenberghs B, Vranckx L, Willebrords R, Ristic Z, Lill H, Dorange I, Guillemont J, Bald D, Andries K. 2007. Diarylquinolines target subunit c of mycobacterial ATP synthase. *Nat Chem Biol* 3:323–324 <http://dx.doi.org/10.1038/nchembio884>.
13. Koul A, Vranckx L, Dendouga N, Balemans W, Van den Wyngaert I, Vergauwen K, Göhlmann HW, Willebrords R, Poncelet A, Guillemont J, Bald D, Andries K. 2008. Diarylquinolines are bactericidal for dormant mycobacteria as a result of disturbed ATP homeostasis. *J Biol Chem* 283:25273–25280 <http://dx.doi.org/10.1074/jbc.M803899200>.
14. Huitric E, Verhasselt P, Andries K, Hoffner SE. 2007. *In vitro* antimycobacterial spectrum of a diarylquinoline ATP synthase inhibitor. *Antimicrob Agents Chemother* 51:4202–4204 <http://dx.doi.org/10.1128/AAC.00181-07>.
15. Huitric E, Verhasselt P, Koul A, Andries K, Hoffner S, Andersson DI. 2010. Rates and mechanisms of resistance development in *Mycobacterium tuberculosis* to a novel diarylquinoline ATP synthase inhibitor. *Antimicrob Agents Chemother* 54:1022–1028 <http://dx.doi.org/10.1128/AAC.01611-09>.
16. Preiss L, Langer JD, Yildiz Ö, Eckhardt-Strelau L, Guillemont JE, Koul A, Meier T. 2015. Structure of the mycobacterial ATP synthase Fo rotor ring in complex with the anti-TB drug bedaquiline. *Sci Adv* 1:e1500106 <http://dx.doi.org/10.1126/sciadv.1500106>.
17. Hards K, Robson JR, Berney M, Shaw L, Bald D, Koul A, Andries K, Cook GM. 2015. Bactericidal mode of action of bedaquiline. *J Antimicrob Chemother* 70:2028–2037.
18. Feng X, Zhu W, Schurig-Briccio LA, Lindert S, Shoen C, Hitchings R, Li J, Wang Y, Baig N, Zhou T, Kim BK, Crick DC, Cynamon M, McCammon JA, Gennis RB, Oldfield E. 2015. Anti-infectives targeting enzymes and the proton motive force. *Proc Natl Acad Sci USA* 112:E7073–E7082.
19. Darby CM, Ingólfsson HI, Jiang X, Shen C, Sun M, Zhao N, Burns K, Liu G, Ehrh S, Warren JD, Andersen OS, Brickner SJ, Nathan C. 2013. Whole cell screen for inhibitors of pH homeostasis in *Mycobacterium tuberculosis*. *PLoS One* 8:e68942 <http://dx.doi.org/10.1371/journal.pone.0068942>.
20. Weinstein EA, Yano T, Li LS, Avarbock D, Avarbock A, Helm D, McColm AA, Duncan K, Lonsdale JT, Rubin H. 2005. Inhibitors of type II NADH:menaquinone oxidoreductase represent a class of antitubercular drugs. *Proc Natl Acad Sci USA* 102:4548–4553 <http://dx.doi.org/10.1073/pnas.0500469102>.
21. Cole ST, Eiglmeier K, Parkhill J, James KD, Thomson NR, Wheeler PR, Honoré N, Garnier T, Churcher C, Harris D, Mungall K, Basham D, Brown D, Chillingworth T, Connor R, Davies RM, Devlin K, Duthoy S, Feltwell T, Fraser A, Hamlin N, Holroyd S, Hornsby T, Jagels K, Lacroix C, Maclean J, Moule S, Murphy L, Oliver K, Quail MA, Rajandream MA, Rutherford KM, Rutter S, Seeger K, Simon S, Simmonds M, Skelton J, Squares R, Squares S, Stevens K, Taylor K, Whitehead S, Woodward JR, Barrell BG. 2001. Massive gene decay in the leprosy bacillus. *Nature* 409:1007–1011 <http://dx.doi.org/10.1038/35059006>.
22. Velmurugan K, Chen B, Miller JL, Azogue S, Gurses S, Hsu T, Glickman M, Jacobs WR Jr, Porcelli SA, Briken V. 2007. *Mycobacterium tuberculosis* nuoG is a virulence gene that inhibits apoptosis of infected host cells. *PLoS Pathog* 3:e110 <http://dx.doi.org/10.1371/journal.ppat.0030110>.
23. Yano T, Li LS, Weinstein E, Teh JS, Rubin H. 2006. Steady-state kinetics and inhibitory action of antitubercular phenothiazines on mycobacterium tuberculosis type-II NADH-menaquinone oxidoreductase (NDH-2). *J Biol Chem* 281:11456–11463 <http://dx.doi.org/10.1074/jbc.M508844200>.
24. Yano T, Rahimian M, Aneja KK, Schechter NM, Rubin H, Scott CP. 2014. *Mycobacterium tuberculosis* type II NADH-menaquinone oxidoreductase catalyzes electron transfer through a two-site ping-pong mechanism and has two quinone-binding sites. *Biochemistry* 53:1179–1190 <http://dx.doi.org/10.1021/bi4013897>.
25. Sasseti CM, Boyd DH, Rubin EJ. 2003. Genes required for mycobacterial growth defined by high density mutagenesis. *Mol Microbiol* 48:77–84 <http://dx.doi.org/10.1046/j.1365-2958.2003.03425.x>.
26. Griffin JE, Gawronski JD, Dejesus MA, Ioerger TR, Akerley BJ, Sasseti CM. 2011. High-resolution phenotypic profiling defines genes essential for mycobacterial growth and cholesterol catabolism. *PLoS Pathog* 7:e1002251 <http://dx.doi.org/10.1371/journal.ppat.1002251>.
27. Warman AJ, Rito TS, Fisher NE, Moss DM, Berry NG, O'Neill PM, Ward SA, Biagini GA. 2013. Antitubercular pharmacodynamics of phenothiazines. *J Antimicrob Chemother* 68:869–880 <http://dx.doi.org/10.1093/jac/dks483>.
28. Teh JS, Yano T, Rubin H. 2007. Type II NADH: menaquinone oxidoreductase of *Mycobacterium tuberculosis*. *Infect Disord Drug Targets* 7:169–181 <http://dx.doi.org/10.2174/187152607781001781>.
29. Dunn EA, Roxburgh M, Larsen L, Smith RA, McLellan AD, Heikal A, Murphy MP, Cook GM. 2014. Incorporation of triphenylphosphonium functionality improves the inhibitory properties of phenothiazine derivatives in *Mycobacterium tuberculosis*. *Bioorg Med Chem* 22:5320–5328 <http://dx.doi.org/10.1016/j.bmc.2014.07.050>.
30. Shirude PS, Paul B, Roy Choudhury N, Kedari C, Bandodkar B, Ugarkar BG. 2012. Quinoliny pyrimidines: potent inhibitors of NDH-2 as a novel class of anti-TB agents. *ACS Med Chem Lett* 3:736–740 <http://dx.doi.org/10.1021/ml300134b>.
31. Ordway D, Viveiros M, Leandro C, Bettencourt R, Almeida J, Martins M, Kristiansen JE, Molnar J, Amaral L. 2003. Clinical concentrations of thioridazine kill intracellular multidrug-resistant *Mycobacterium tuberculosis*. *Antimicrob Agents Chemother* 47:917–922 <http://dx.doi.org/10.1128/AAC.47.3.917-922.2003>.
32. Amaral L, Kristiansen JE, Abebe LS, Millett W. 1996. Inhibition of the respiration of multi-drug resistant clinical isolates of *Mycobacterium tuberculosis* by thioridazine: potential use for initial therapy of freshly diagnosed tuberculosis. *J Antimicrob Chemother* 38:1049–1053 <http://dx.doi.org/10.1093/jac/38.6.1049>.
33. Bettencourt MV, Bosne-David S, Amaral L. 2000. Comparative *in vitro* activity of phenothiazines against multidrug-resistant *Mycobacterium tuberculosis*. *Int J Antimicrob Agents* 16:69–71 [http://dx.doi.org/10.1016/S0924-8579\(00\)00199-0](http://dx.doi.org/10.1016/S0924-8579(00)00199-0).
34. Madrid PB, Polgar WE, Toll L, Tanga MJ. 2007. Synthesis and antitubercular activity of phenothiazines with reduced binding to dopamine and serotonin receptors. *Bioorg Med Chem Lett* 17:3014–3017 <http://dx.doi.org/10.1016/j.bmcl.2007.03.064>.

35. Mogi T, Matsushita K, Murase Y, Kawahara K, Miyoshi H, Ui H, Shiomi K, Omura S, Kita K. 2009. Identification of new inhibitors for alternative NADH dehydrogenase (NDH-II). *FEMS Microbiol Lett* 291: 157–161 <http://dx.doi.org/10.1111/j.1574-6968.2008.01451.x>.
36. Mogi T, Murase Y, Mori M, Shiomi K, Omura S, Paranagama MP, Kita K. 2009. Polymyxin B identified as an inhibitor of alternative NADH dehydrogenase and malate: quinone oxidoreductase from the Gram-positive bacterium *Mycobacterium smegmatis*. *J Biochem* 146:491–499 <http://dx.doi.org/10.1093/jb/mvp096>.
37. Yano T, Kassovska-Bratinova S, Teh JS, Winkler J, Sullivan K, Isaacs A, Schechter NM, Rubin H. 2011. Reduction of clofazimine by mycobacterial type 2 NADH:quinone oxidoreductase: a pathway for the generation of bactericidal levels of reactive oxygen species. *J Biol Chem* 286:10276–10287 <http://dx.doi.org/10.1074/jbc.M110.200501>.
38. Hartkoorn RC, Uplekar S, Cole ST. 2014. Cross-resistance between clofazimine and bedaquiline through upregulation of MmpL5 in *Mycobacterium tuberculosis*. *Antimicrob Agents Chemother* 58:2979–2981 <http://dx.doi.org/10.1128/AAC.00037-14>.
39. Vilchèze C, Weisbrod TR, Chen B, Kremer L, Hazbón MH, Wang F, Alland D, Sacchettini JC, Jacobs WR Jr. 2005. Altered NADH/NAD⁺ ratio mediates coresistance to isoniazid and ethionamide in mycobacteria. *Antimicrob Agents Chemother* 49:708–720 <http://dx.doi.org/10.1128/AAC.49.2.708-720.2005>.
40. Heikal A, Nakatani Y, Dunn E, Weimar MR, Day CL, Baker EN, Lott JS, Sazanov LA, Cook GM. 2014. Structure of the bacterial type II NADH dehydrogenase: a monotopic membrane protein with an essential role in energy generation. *Mol Microbiol* 91:950–964 <http://dx.doi.org/10.1111/mmi.12507>.
41. Sena FV, Batista AP, Catarino T, Brito JA, Archer M, Viertler M, Madl T, Cabrera EJ, Pereira MM. 2015. Type-II NADH:quinone oxidoreductase from *Staphylococcus aureus* has two distinct binding sites and is rate limited by quinone reduction. *Mol Microbiol* 98:272–288 <http://dx.doi.org/10.1111/mmi.13120>.
42. Anderson AC. 2003. The process of structure-based drug design. *Chem Biol* 10:787–797 <http://dx.doi.org/10.1016/j.chembiol.2003.09.002>.
43. Feng Y, Li W, Li J, Wang J, Ge J, Xu D, Liu Y, Wu K, Zeng Q, Wu JW, Tian C, Zhou B, Yang M. 2012. Structural insight into the type-II mitochondrial NADH dehydrogenases. *Nature* 491:478–482 <http://dx.doi.org/10.1038/nature11541>.
44. Maklashina E, Cecchini G, Dikanov SA. 2013. Defining a direction: electron transfer and catalysis in *Escherichia coli* complex II enzymes. *Biochim Biophys Acta* 1827:668–678 <http://dx.doi.org/10.1016/j.bbabi.2013.01.010>.
45. Lancaster CR. 2013. The di-heme family of respiratory complex II enzymes. *Biochim Biophys Acta* 1827:679–687 <http://dx.doi.org/10.1016/j.bbabi.2013.02.012>.
46. Hartman T, Weinrick B, Vilchèze C, Berney M, Tufariello J, Cook GM, Jacobs WR Jr. 2014. Succinate dehydrogenase is the regulator of respiration in *Mycobacterium tuberculosis*. *PLoS Pathog* 10:e1004510 <http://dx.doi.org/10.1371/journal.ppat.1004510>.
47. Eoh H, Rhee KY. 2013. Multifunctional essentiality of succinate metabolism in adaptation to hypoxia in *Mycobacterium tuberculosis*. *Proc Natl Acad Sci USA* 110:6554–6559 <http://dx.doi.org/10.1073/pnas.1219375110>.
48. Hägerhäll C. 1997. Succinate: quinone oxidoreductases. Variations on a conserved theme. *Biochim Biophys Acta* 1320:107–141 [http://dx.doi.org/10.1016/S0005-2728\(97\)00019-4](http://dx.doi.org/10.1016/S0005-2728(97)00019-4).
49. Lemos RS, Fernandes AS, Pereira MM, Gomes CM, Teixeira M. 2002. Quinol:fumarate oxidoreductases and succinate:quinone oxidoreductases: phylogenetic relationships, metal centres and membrane attachment. *Biochim Biophys Acta* 1553:158–170 [http://dx.doi.org/10.1016/S0005-2728\(01\)00239-0](http://dx.doi.org/10.1016/S0005-2728(01)00239-0).
50. Huang LS, Sun G, Cobessi D, Wang AC, Shen JT, Tung EY, Anderson VE, Berry EA. 2006. 3-nitropropionic acid is a suicide inhibitor of mitochondrial respiration that, upon oxidation by complex II, forms a covalent adduct with a catalytic base arginine in the active site of the enzyme. *J Biol Chem* 281:5965–5972 <http://dx.doi.org/10.1074/jbc.M511270200>.
51. Alston TA, Mela L, Bright HJ. 1977. 3-Nitropropionate, the toxic substance of *Indigofera*, is a suicide inactivator of succinate dehydrogenase. *Proc Natl Acad Sci USA* 74:3767–3771 <http://dx.doi.org/10.1073/pnas.74.9.3767>.
52. Cecchini G, Schröder I, Gunsalus RP, Maklashina E. 2002. Succinate dehydrogenase and fumarate reductase from *Escherichia coli*. *Biochim Biophys Acta* 1553:140–157 [http://dx.doi.org/10.1016/S0005-2728\(01\)00238-9](http://dx.doi.org/10.1016/S0005-2728(01)00238-9).
53. Park SW, Hwang EH, Park H, Kim JA, Heo J, Lee KH, Song T, Kim E, Ro YT, Kim SW, Kim YM. 2003. Growth of mycobacteria on carbon monoxide and methanol. *J Bacteriol* 185:142–147 <http://dx.doi.org/10.1128/JB.185.1.142-147.2003>.
54. Kim YM, Hegeman GD. 1983. Oxidation of carbon monoxide by bacteria. *Int Rev Cytol* 81:1–32 [http://dx.doi.org/10.1016/S0074-7696\(08\)62333-5](http://dx.doi.org/10.1016/S0074-7696(08)62333-5).
55. Ragsdale SW. 2004. Life with carbon monoxide. *Crit Rev Biochem Mol Biol* 39:165–195 <http://dx.doi.org/10.1080/10409230490496577>.
56. Park SW, Song T, Kim SY, Kim E, Oh JI, Eom CY, Kim YM. 2007. Carbon monoxide dehydrogenase in mycobacteria possesses a nitric oxide dehydrogenase activity. *Biochem Biophys Res Commun* 362:449–453 <http://dx.doi.org/10.1016/j.bbrc.2007.08.011>.
57. Dobbek H, Svetlitchnyi V, Gremer L, Huber R, Meyer O. 2001. Crystal structure of a carbon monoxide dehydrogenase reveals a [Ni-4Fe-5S] cluster. *Science* 293:1281–1285 <http://dx.doi.org/10.1126/science.1061500>.
58. Dobbek H, Svetlitchnyi V, Liss J, Meyer O. 2004. Carbon monoxide induced decomposition of the active site [Ni-4Fe-5S] cluster of CO dehydrogenase. *J Am Chem Soc* 126:5382–5387 <http://dx.doi.org/10.1021/ja037776v>.
59. Santiago B, Schübel U, Egelseer C, Meyer O. 1999. Sequence analysis, characterization and CO-specific transcription of the *cox* gene cluster on the megaplasmid pHCG3 of *Oligotropha carboxidovorans*. *Gene* 236:115–124 [http://dx.doi.org/10.1016/S0378-1119\(99\)00245-0](http://dx.doi.org/10.1016/S0378-1119(99)00245-0).
60. Oh JI, Park SJ, Shin SJ, Ko IJ, Han SJ, Park SW, Song T, Kim YM. 2010. Identification of trans- and cis-control elements involved in regulation of the carbon monoxide dehydrogenase genes in *Mycobacterium* sp. strain JC1 DSM 3803. *J Bacteriol* 192:3925–3933 <http://dx.doi.org/10.1128/JB.00286-10>.
61. Zhang YJ, Ioerger TR, Huttenhower C, Long JE, Sassetti CM, Sacchettini JC, Rubin EJ. 2012. Global assessment of genomic regions required for growth in *Mycobacterium tuberculosis*. *PLoS Pathog* 8:e1002946 <http://dx.doi.org/10.1371/journal.ppat.1002946>. (Erratum, 9:10.1371/annotation/4669e9e7-fd12-4a01-be2a-617b956ec0bb. doi:10.1371/annotation/4669e9e7-fd12-4a01-be2a-617b956ec0bb.)
62. Shiloh MU, Manzanillo P, Cox JS. 2008. *Mycobacterium tuberculosis* senses host-derived carbon monoxide during macrophage infection. *Cell Host Microbe* 3:323–330 <http://dx.doi.org/10.1016/j.chom.2008.03.007>.
63. Sousa EH, Tuckerman JR, Gonzalez G, Gilles-Gonzalez MA. 2007. DosT and DevS are oxygen-switched kinases in *Mycobacterium tuberculosis*. *Protein Sci* 16:1708–1719 <http://dx.doi.org/10.1110/ps.072897707>.
64. Kumar A, Deshane JS, Crossman DK, Bolisetty S, Yan BS, Kramnik I, Agarwal A, Steyn AJ. 2008. Heme oxygenase-1-derived carbon monoxide induces the *Mycobacterium tuberculosis* dormancy regulon. *J Biol Chem* 283:18032–18039 <http://dx.doi.org/10.1074/jbc.M802274200>.
65. Kumar A, Toledo JC, Patel RP, Lancaster JR Jr, Steyn AJ. 2007. *Mycobacterium tuberculosis* DosS is a redox sensor and DosT is a hypoxia sensor. *Proc Natl Acad Sci USA* 104:11568–11573 <http://dx.doi.org/10.1073/pnas.0705054104>.
66. Shi T, Xie J. 2011. Molybdenum enzymes and molybdenum cofactor in mycobacteria. *J Cell Biochem* 112:2721–2728 <http://dx.doi.org/10.1002/jcb.23233>.

67. Dobbek H, Gremer L, Kiefersauer R, Huber R, Meyer O. 2002. Catalysis at a dinuclear [CuSMo(=O)OH] cluster in a CO dehydrogenase resolved at 1.1-Å resolution. *Proc Natl Acad Sci USA* 99:15971–15976 <http://dx.doi.org/10.1073/pnas.212640899>.
68. Ahmed FH, Carr PD, Lee BM, Afriat-Jurnou L, Mohamed AE, Hong NS, Flanagan J, Taylor MC, Greening C, Jackson CJ. 2015. Sequence-structure-function classification of a catalytically diverse oxidoreductase superfamily in mycobacteria. *J Mol Biol* 427:3554–3571 <http://dx.doi.org/10.1016/j.jmb.2015.09.021>.
69. Purwantini E, Gillis TP, Daniels L. 1997. Presence of F420-dependent glucose-6-phosphate dehydrogenase in *Mycobacterium* and *Nocardia* species, but absence from *Streptomyces* and *Corynebacterium* species and methanogenic Archaea. *FEMS Microbiol Lett* 146:129–134 <http://dx.doi.org/10.1111/j.1574-6968.1997.tb10182.x>.
70. Taylor MC, Jackson CJ, Tattersall DB, French N, Peat TS, Newman J, Briggs LJ, Lalapikar GV, Campbell PM, Scott C, Russell RJ, Oakeshott JG. 2010. Identification and characterization of two families of F₄₂₀ H₂-dependent reductases from mycobacteria that catalyse aflatoxin degradation. *Mol Microbiol* 78:561–575 <http://dx.doi.org/10.1111/j.1365-2958.2010.07356.x>.
71. Cellitti SE, Shaffer J, Jones DH, Mukherjee T, Gurumurthy M, Bursulaya B, Boshoff HI, Choi I, Nayyar A, Lee YS, Cherian J, Niyomrattanakit P, Dick T, Manjunatha UH, Barry CE III, Spraggon G, Geierstanger BH. 2012. Structure of Ddn, the deazaflavin-dependent nitroreductase from *Mycobacterium tuberculosis* involved in bioreductive activation of PA-824. *Structure* 20:101–112 <http://dx.doi.org/10.1016/j.str.2011.11.001>.
72. Gurumurthy M, Rao M, Mukherjee T, Rao SP, Boshoff HI, Dick T, Barry CE III, Manjunatha UH. 2013. A novel F(420)-dependent anti-oxidant mechanism protects *Mycobacterium tuberculosis* against oxidative stress and bactericidal agents. *Mol Microbiol* 87:744–755 <http://dx.doi.org/10.1111/mmi.12127>.
73. Purwantini E, Mukhopadhyay B. 2009. Conversion of NO₂ to NO by reduced coenzyme F420 protects mycobacteria from nitrosative damage. *Proc Natl Acad Sci USA* 106:6333–6338 <http://dx.doi.org/10.1073/pnas.0812883106>.
74. Hasan MR, Rahman M, Jaques S, Purwantini E, Daniels L. 2010. Glucose 6-phosphate accumulation in mycobacteria: implications for a novel F420-dependent anti-oxidant defense system. *J Biol Chem* 285:19135–19144 <http://dx.doi.org/10.1074/jbc.M109.074310>.
75. Stover CK, Warren P, VanDevanter DR, Sherman DR, Arain TM, Langhorne MH, Anderson SW, Towell JA, Yuan Y, McMurray DN, Kreiswirth BN, Barry CE, Baker WR. 2000. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. *Nature* 405:962–966 <http://dx.doi.org/10.1038/35016103>.
76. Singh R, Manjunatha U, Boshoff HI, Ha YH, Niyomrattanakit P, Ledwidge R, Dowd CS, Lee IY, Kim P, Zhang L, Kang S, Keller TH, Jiricek J, Barry CE III. 2008. PA-824 kills nonreplicating *Mycobacterium tuberculosis* by intracellular NO release. *Science* 322:1392–1395 <http://dx.doi.org/10.1126/science.1164571>.
77. Gurumurthy M, Mukherjee T, Dowd CS, Singh R, Niyomrattanakit P, Tay JA, Nayyar A, Lee YS, Cherian J, Boshoff HI, Dick T, Barry CE III, Manjunatha UH. 2012. Substrate specificity of the deazaflavin-dependent nitroreductase from *Mycobacterium tuberculosis* responsible for the bioreductive activation of bicyclic nitroimidazoles. *FEBS J* 279:113–125 <http://dx.doi.org/10.1111/j.1742-4658.2011.08404.x>.
78. Lewis JM, Sloan DJ. 2015. The role of delamanid in the treatment of drug-resistant tuberculosis. *Ther Clin Risk Manag* 11:779–791.
79. Bloemberg GV, Keller PM, Stucki D, Trauner A, Borrell S, Latshang T, Coscolla M, Rothe T, Hönke R, Ritter C, Feldmann J, Schulthess B, Gagneux S, Böttger EC. 2015. Acquired resistance to bedaquiline and delamanid in therapy for tuberculosis. *N Engl J Med* 373:1986–1988 <http://dx.doi.org/10.1056/NEJMc1505196>.
80. Mak PA, Rao SP, Ping Tan M, Lin X, Chyba J, Tay J, Ng SH, Tan BH, Cherian J, Duraiswamy J, Bifani P, Lim V, Lee BH, Ling Ma N, Beer D, Thayalan P, Kuhen K, Chatterjee A, Supak F, Glynn R, Zheng J, Boshoff HI, Barry CE III, Dick T, Pethe K, Camacho LR. 2012. A high-throughput screen to identify inhibitors of ATP homeostasis in non-replicating *Mycobacterium tuberculosis*. *ACS Chem Biol* 7:1190–1197 <http://dx.doi.org/10.1021/cb2004884>.
81. Molenaar D, van der Rest ME, Drysch A, Yücel R. 2000. Functions of the membrane-associated and cytoplasmic malate dehydrogenases in the citric acid cycle of *Corynebacterium glutamicum*. *J Bacteriol* 182:6884–6891 <http://dx.doi.org/10.1128/JB.182.24.6884-6891.2000>.
82. van der Rest ME, Frank C, Molenaar D. 2000. Functions of the membrane-associated and cytoplasmic malate dehydrogenases in the citric acid cycle of *Escherichia coli*. *J Bacteriol* 182:6892–6899 <http://dx.doi.org/10.1128/JB.182.24.6892-6899.2000>.
83. Berney M, Weimar MR, Heikal A, Cook GM. 2012. Regulation of proline metabolism in mycobacteria and its role in carbon metabolism under hypoxia. *Mol Microbiol* 84:664–681 <http://dx.doi.org/10.1111/j.1365-2958.2012.08053.x>.
84. Collins MD, Jones D. 1981. Distribution of isoprenoid quinone structural types in bacteria and their taxonomic implication. *Microbiol Rev* 45:316–354.
85. Anand A, Verma P, Singh AK, Kaushik S, Pandey R, Shi C, Kaur H, Chawla M, Elechalawar CK, Kumar D, Yang Y, Bhavesh NS, Banerjee R, Dash D, Singh A, Natarajan VT, Ojha AK, Aldrich CC, Gokhale RS. 2015. Polyketide quinones are alternate intermediate electron carriers during mycobacterial respiration in oxygen-deficient niches. *Mol Cell* 60:637–650 <http://dx.doi.org/10.1016/j.molcel.2015.10.016>.
86. Upadhyay A, Fontes FL, Gonzalez-Juarrero M, McNeil MR, Crans DC, Jackson M, Crick DC. 2015. Partial saturation of menaquinone in *Mycobacterium tuberculosis*: function and essentiality of a novel reductase. *MenJ. ACS Cent Sci* 1:292–302 <http://dx.doi.org/10.1021/acscentsci.5b00212>.
87. Chen M, Ma X, Chen X, Jiang M, Song H, Guo Z. 2013. Identification of a hotdog fold thioesterase involved in the biosynthesis of menaquinone in *Escherichia coli*. *J Bacteriol* 195:2768–2775 <http://dx.doi.org/10.1128/JB.00141-13>.
88. Dhiman RK, Mahapatra S, Slayden RA, Boyne ME, Lenaerts A, Hinshaw JC, Angala SK, Chatterjee D, Biswas K, Narayanasamy P, Kurosu M, Crick DC. 2009. Menaquinone synthesis is critical for maintaining mycobacterial viability during exponential growth and recovery from non-replicating persistence. *Mol Microbiol* 72:85–97 <http://dx.doi.org/10.1111/j.1365-2958.2009.06625.x>.
89. Debnath J, Siricilla S, Wan B, Crick DC, Lenaerts AJ, Franzblau SG, Kurosu M. 2012. Discovery of selective menaquinone biosynthesis inhibitors against *Mycobacterium tuberculosis*. *J Med Chem* 55:3739–3755 <http://dx.doi.org/10.1021/jm201608g>.
90. Lu X, Zhou R, Sharma I, Li X, Kumar G, Swaminathan S, Tonge PJ, Tan DS. 2012. Stable analogues of OSB-AMP: potent inhibitors of MenE, the o-succinylbenzoate-CoA synthetase from bacterial menaquinone biosynthesis. *ChemBioChem* 13:129–136 <http://dx.doi.org/10.1002/cbic.201100585>.
91. Lu X, Zhang H, Tonge PJ, Tan DS. 2008. Mechanism-based inhibitors of MenE, an acyl-CoA synthetase involved in bacterial menaquinone biosynthesis. *Bioorg Med Chem Lett* 18:5963–5966 <http://dx.doi.org/10.1016/j.bmcl.2008.07.130>.
92. Truglio JJ, Theis K, Feng Y, Gajda R, Machutta C, Tonge PJ, Kisker C. 2003. Crystal structure of *Mycobacterium tuberculosis* MenB, a key enzyme in vitamin K2 biosynthesis. *J Biol Chem* 278:42352–42360 <http://dx.doi.org/10.1074/jbc.M307399200>.
93. Sasseti CM, Rubin EJ. 2003. Genetic requirements for mycobacterial survival during infection. *Proc Natl Acad Sci USA* 100:12989–12994 <http://dx.doi.org/10.1073/pnas.2134250100>.
94. Jiang M, Cao Y, Guo ZF, Chen M, Chen X, Guo Z. 2007. Menaquinone biosynthesis in *Escherichia coli*: identification of 2-succinyl-5-enolpyruvyl-6-hydroxy-3-cyclohexene-1-carboxylate as a novel intermediate and re-evaluation of MenD activity. *Biochemistry* 46:10979–10989 <http://dx.doi.org/10.1021/bi700810x>.

95. Rengarajan J, Bloom BR, Rubin EJ. 2005. Genome-wide requirements for *Mycobacterium tuberculosis* adaptation and survival in macrophages. *Proc Natl Acad Sci USA* 102:8327–8332 <http://dx.doi.org/10.1073/pnas.0503272102>.
96. Mougous JD, Senaratne RH, Petzold CJ, Jain M, Lee DH, Schelle MW, Leavell MD, Cox JS, Leary JA, Riley LW, Bertozzi CR. 2006. A sulfated metabolite produced by *stf3* negatively regulates the virulence of *Mycobacterium tuberculosis*. *Proc Natl Acad Sci USA* 103:4258–4263 <http://dx.doi.org/10.1073/pnas.05108611103>.
97. Bott M, Niebisch A. 2003. The respiratory chain of *Corynebacterium glutamicum*. *J Biotechnol* 104:129–153 [http://dx.doi.org/10.1016/S0168-1656\(03\)00144-5](http://dx.doi.org/10.1016/S0168-1656(03)00144-5).
98. Niebisch A, Bott M. 2003. Purification of a cytochrome bc-aa3 supercomplex with quinol oxidase activity from *Corynebacterium glutamicum*. Identification of a fourth subunit of cytochrome aa3 oxidase and mutational analysis of di-heme cytochrome c1. *J Biol Chem* 278:4339–4346 <http://dx.doi.org/10.1074/jbc.M210499200>.
99. Kim MS, Jang J, Ab Rahman NB, Pethe K, Berry EA, Huang LS. 2015. Isolation and characterization of a hybrid respiratory supercomplex consisting of *Mycobacterium tuberculosis* cytochrome bcc and *Mycobacterium smegmatis* cytochrome aa3. *J Biol Chem* 290:14350–14360 <http://dx.doi.org/10.1074/jbc.M114.624312>.
100. Megehee JA, Hosler JP, Lundrigan MD. 2006. Evidence for a cytochrome bcc-aa3 interaction in the respiratory chain of *Mycobacterium smegmatis*. *Microbiology* 152:823–829 <http://dx.doi.org/10.1099/mic.0.28723-0>.
101. Niebisch A, Bott M. 2001. Molecular analysis of the cytochrome bc₁-aa₃ branch of the *Corynebacterium glutamicum* respiratory chain containing an unusual di-heme cytochrome c₁. *Arch Microbiol* 175:282–294 <http://dx.doi.org/10.1007/s002030100262>.
102. Matsoso LG, Kana BD, Crellin PK, Lea-Smith DJ, Pelosi A, Powell D, Dawes SS, Rubin H, Coppel RL, Mizrahi V. 2005. Function of the cytochrome bc₁-aa₃ branch of the respiratory network in mycobacteria and network adaptation occurring in response to its disruption. *J Bacteriol* 187:6300–6308 <http://dx.doi.org/10.1128/JB.187.18.6300-6308.2005>.
103. Small JL, Park SW, Kana BD, Ioerger TR, Sacchettini JC, Ehrt S. 2013. Perturbation of cytochrome c maturation reveals adaptability of the respiratory chain in *Mycobacterium tuberculosis*. *MBio* 4:e00475-13 <http://dx.doi.org/10.1128/mBio.00475-13>.
104. Abrahams KA, Cox JA, Spivey VL, Loman NJ, Pallen MJ, Constantinidou C, Fernández R, Alemparte C, Remuñán MJ, Barros D, Ballell L, Besra GS. 2012. Identification of novel imidazo[1,2-a]pyridine inhibitors targeting *M. tuberculosis* QcrB. *PLoS One* 7:e2951 <http://dx.doi.org/10.1371/journal.pone.0052951>.
105. Arora K, Ochoa-Montañón B, Tsang PS, Blundell TL, Dawes SS, Mizrahi V, Bayliss T, Mackenzie CJ, Cleghorn LA, Ray PC, Wyatt PG, Uh E, Lee J, Barry CE III, Boshoff HI. 2014. Respiratory flexibility in response to inhibition of cytochrome c oxidase in *Mycobacterium tuberculosis*. *Antimicrob Agents Chemother* 58:6962–6965 <http://dx.doi.org/10.1128/AAC.03486-14>.
106. Pethe K, et al. 2013. Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis. *Nat Med* 19:1157–1160 <http://dx.doi.org/10.1038/nm.3262>.
107. Rybníček J, Vocat A, Sala C, Busso P, Pojer F, Benjak A, Cole ST. 2015. Lansoprazole is an antituberculous prodrug targeting cytochrome bc₁. *Nat Commun* 6:7659 <http://dx.doi.org/10.1038/ncomms8659>.
108. Moraski GC, Markley LD, Cramer J, Hipskind PA, Boshoff H, Bailey M, Alling T, Ollinger J, Parish T, Miller MJ. 2013. Advancement of imidazo[1,2-a]pyridines with improved pharmacokinetics and nM activity vs. *Mycobacterium tuberculosis*. *ACS Med Chem Lett* 4:675–679 <http://dx.doi.org/10.1021/ml400088y>.
109. Kang S, Kim RY, Seo MJ, Lee S, Kim YM, Seo M, Seo JJ, Ko Y, Choi I, Jang J, Nam J, Park S, Kang H, Kim HJ, Kim J, Ahn S, Pethe K, Nam K, No Z, Kim J. 2014. Lead optimization of a novel series of imidazo[1,2-a]pyridine amides leading to a clinical candidate (Q203) as a multi- and extensively-drug resistant antituberculosis agent. *J Med Chem* 57:5293–5305 <http://dx.doi.org/10.1021/jm5003606>.
110. Demangel C, Stinear TP, Cole ST. 2009. Buruli ulcer: reductive evolution enhances pathogenicity of *Mycobacterium ulcerans*. *Nat Rev Microbiol* 7:50–60 <http://dx.doi.org/10.1038/nrmicro2077>.
111. Kana BD, Weinstein EA, Avarbock D, Dawes SS, Rubin H, Mizrahi V. 2001. Characterization of the cydAB-encoded cytochrome bd oxidase from *Mycobacterium smegmatis*. *J Bacteriol* 183:7076–7086 <http://dx.doi.org/10.1128/JB.183.24.7076-7086.2001>.
112. Poole RK, Cook GM. 2000. Redundancy of aerobic respiratory chains in bacteria? Routes, reasons and regulation. *Adv Microb Physiol* 43:165–224 [http://dx.doi.org/10.1016/S0065-2911\(00\)43005-5](http://dx.doi.org/10.1016/S0065-2911(00)43005-5).
113. Borisov VB, Murali R, Verkhovskaya ML, Bloch DA, Han H, Gennis RB, Verkhovsky MI. 2011. Aerobic respiratory chain of *Escherichia coli* is not allowed to work in fully uncoupled mode. *Proc Natl Acad Sci USA* 108:17320–17324 <http://dx.doi.org/10.1073/pnas.1108217108>.
114. Holyoake LV, Poole RK, Shepherd M. 2015. The CydDC family of transporters and their roles in oxidase assembly and homeostasis. *Adv Microb Physiol* 66:1–53 <http://dx.doi.org/10.1016/bs.ampbs.2015.04.002>.
115. Borisov VB, Gennis RB, Hemp J, Verkhovsky MI. 2011. The cytochrome bd respiratory oxygen reductases. *Biochim Biophys Acta* 1807:1398–1413 <http://dx.doi.org/10.1016/j.bbabi.2011.06.016>.
116. Cook GM, Greening C, Hards K, Berney M. 2014. Energetics of pathogenic bacteria and opportunities for drug development. *Adv Microb Physiol* 65:1–62 <http://dx.doi.org/10.1016/bs.ampbs.2014.08.001>.
117. Giuffrè A, Borisov VB, Arese M, Sarti P, Forte E. 2014. Cytochrome bd oxidase and bacterial tolerance to oxidative and nitrosative stress. *Biochim Biophys Acta* 1837:1178–1187.
118. Zhang YJ, Reddy MC, Ioerger TR, Rothchild AC, Dartois V, Schuster BM, Trauner A, Wallis D, Galaviz S, Huttenhower C, Sacchettini JC, Behar SM, Rubin EJ. 2013. Tryptophan biosynthesis protects mycobacteria from CD4 T-cell-mediated killing. *Cell* 155:1296–1308 <http://dx.doi.org/10.1016/j.cell.2013.10.045>.
119. Shi L, Sohaskey CD, Kana BD, Dawes S, North RJ, Mizrahi V, Gennaro ML. 2005. Changes in energy metabolism of *Mycobacterium tuberculosis* in mouse lung and under *in vitro* conditions affecting aerobic respiration. *Proc Natl Acad Sci USA* 102:15629–15634 <http://dx.doi.org/10.1073/pnas.0507850102>.
120. Dhar N, McKinney JD. 2010. *Mycobacterium tuberculosis* persistence mutants identified by screening in isoniazid-treated mice. *Proc Natl Acad Sci USA* 107:12275–12280 <http://dx.doi.org/10.1073/pnas.1003219107>.
121. Berney M, Hartman TE, Jacobs WR Jr. 2014. A *Mycobacterium tuberculosis* cytochrome bd oxidase mutant is hypersensitive to bedaquiline. *MBio* 5:e01275-14 <http://dx.doi.org/10.1128/mBio.01275-14>.
122. Lu P, Heineke MH, Koul A, Andries K, Cook GM, Lill H, van Spanning R, Bald D. 2015. The cytochrome bd-type quinol oxidase is important for survival of *Mycobacterium smegmatis* under peroxide and antibiotic-induced stress. *Sci Rep* 5:10333 <http://dx.doi.org/10.1038/srep10333>.
123. Voskuil MI, Visconti KC, Schoolnik GK. 2004. *Mycobacterium tuberculosis* gene expression during adaptation to stationary phase and low-oxygen dormancy. *Tuberculosis (Edinb)* 84:218–227 <http://dx.doi.org/10.1016/j.tube.2004.02.003>.
124. Wayne LG, Sohaskey CD. 2001. Nonreplicating persistence of *Mycobacterium tuberculosis*. *Annu Rev Microbiol* 55:139–163 <http://dx.doi.org/10.1146/annurev.micro.55.1.139>.
125. Keren I, Kaldalu N, Spoering A, Wang Y, Lewis K. 2004. Persister cells and tolerance to antimicrobials. *FEMS Microbiol Lett* 230:13–18 [http://dx.doi.org/10.1016/S0378-1097\(03\)00856-5](http://dx.doi.org/10.1016/S0378-1097(03)00856-5).
126. Wayne LG, Hayes LG. 1996. An *in vitro* model for sequential study of shutdown of *Mycobacterium tuberculosis* through two stages of nonreplicating persistence. *Infect Immun* 64:2062–2069.

127. Koul A, Vranckx L, Dhar N, Göhlmann HW, Özdemir E, Neefs JM, Schulz M, Lu P, Mørtz E, McKinney JD, Andries K, Bald D. 2014. Delayed bactericidal response of *Mycobacterium tuberculosis* to bedaquiline involves remodelling of bacterial metabolism. *Nat Commun* 5:3369 <http://dx.doi.org/10.1038/ncomms4369>.
128. Boshoff HI, Myers TG, Copp BR, McNeil MR, Wilson MA, Barry CE III. 2004. The transcriptional responses of *Mycobacterium tuberculosis* to inhibitors of metabolism: novel insights into drug mechanisms of action. *J Biol Chem* 279:40174–40184 <http://dx.doi.org/10.1074/jbc.M406796200>.
129. Aung HL, Berney M, Cook GM. 2014. Hypoxia-activated cytochrome *bd* expression in *Mycobacterium smegmatis* is cyclic AMP receptor protein dependent. *J Bacteriol* 196:3091–3097 <http://dx.doi.org/10.1128/JB.01771-14>.
130. Barry CE III, Boshoff HI, Dartois V, Dick T, Ehrt S, Flynn J, Schnappinger D, Wilkinson RJ, Young D. 2009. The spectrum of latent tuberculosis: rethinking the biology and intervention strategies. *Nat Rev Microbiol* 7:845–855.
131. Boshoff HI, Barry CE III. 2005. Tuberculosis: metabolism and respiration in the absence of growth. *Nat Rev Microbiol* 3:70–80 <http://dx.doi.org/10.1038/nrmicro1065>.
132. Gomez JE, McKinney JD. 2004. *M. tuberculosis* persistence, latency, and drug tolerance. *Tuberculosis (Edinb)* 84:29–44 <http://dx.doi.org/10.1016/j.tube.2003.08.003>.
133. Dick T. 2001. Dormant tubercle bacilli: the key to more effective TB chemotherapy? *J Antimicrob Chemother* 47:117–118 <http://dx.doi.org/10.1093/jac/47.1.117>.
134. Meunier B, Madgwick SA, Reil E, Oettmeier W, Rich PR. 1995. New inhibitors of the quinol oxidation sites of bacterial cytochromes *bo* and *bd*. *Biochemistry* 34:1076–1083 <http://dx.doi.org/10.1021/bi00003a044>.
135. Jünemann S, Wigglesworth JM, Rich PR. 1997. Effects of decylaurachin D and reversed electron transfer in cytochrome *bd*. *Biochemistry* 36:9323–9331 <http://dx.doi.org/10.1021/bi970055m>.
136. Jung JY, Madan-Lala R, Georgieva M, Rengarajan J, Sohaskey CD, Bange FC, Robinson CM. 2013. The intracellular environment of human macrophages that produce nitric oxide promotes growth of mycobacteria. *Infect Immun* 81:3198–3209 <http://dx.doi.org/10.1128/IAI.00611-13>.
137. Arya S, Sethi D, Singh S, Hade MD, Singh V, Raju P, Chodiseti SB, Verma D, Varshney GC, Agrewala JN, Dikshit KL. 2013. Truncated hemoglobin, HbN, is post-translationally modified in *Mycobacterium tuberculosis* and modulates host-pathogen interactions during intracellular infection. *J Biol Chem* 288:29987–29999 <http://dx.doi.org/10.1074/jbc.M113.507301>.
138. Malm S, Tiffert Y, Micklinghoff J, Schultze S, Joost I, Weber I, Horst S, Ackermann B, Schmidt M, Wohlleben W, Ehlers S, Geffers R, Reuther J, Bange FC. 2009. The roles of the nitrate reductase NarGHJI, the nitrite reductase NirBD and the response regulator GlnR in nitrate assimilation of *Mycobacterium tuberculosis*. *Microbiology* 155:1332–1339 <http://dx.doi.org/10.1099/mic.0.023275-0>.
139. Sohaskey CD, Wayne LG. 2003. Role of narK2X and narGHJI in hypoxic upregulation of nitrate reduction by *Mycobacterium tuberculosis*. *J Bacteriol* 185:7247–7256 <http://dx.doi.org/10.1128/JB.185.24.7247-7256.2003>.
140. Voskuil MI, Schnappinger D, Visconti KC, Harrell MI, Dolganov GM, Sherman DR, Schoolnik GK. 2003. Inhibition of respiration by nitric oxide induces a *Mycobacterium tuberculosis* dormancy program. *J Exp Med* 198:705–713 <http://dx.doi.org/10.1084/jem.20030205>.
141. Sohaskey CD. 2005. Regulation of nitrate reductase activity in *Mycobacterium tuberculosis* by oxygen and nitric oxide. *Microbiology* 151:3803–3810 <http://dx.doi.org/10.1099/mic.0.28263-0>.
142. Tan MP, Sequeira P, Lin WH, Phong WY, Cliff P, Ng SH, Lee BH, Camacho L, Schnappinger D, Ehrt S, Dick T, Pethe K, Alonso S. 2010. Nitrate respiration protects hypoxic *Mycobacterium tuberculosis* against acid- and reactive nitrogen species stresses. *PLoS One* 5:e13356 <http://dx.doi.org/10.1371/journal.pone.0013356> [doi:10.1038/ncomms4369](http://dx.doi.org/10.1038/ncomms4369).
143. Sohaskey CD. 2008. Nitrate enhances the survival of *Mycobacterium tuberculosis* during inhibition of respiration. *J Bacteriol* 190:2981–2986 <http://dx.doi.org/10.1128/JB.01857-07>.
144. Cunningham-Bussell A, Bange FC, Nathan CF. 2013. Nitrite impacts the survival of *Mycobacterium tuberculosis* in response to isoniazid and hydrogen peroxide. *Microbiologyopen* 2:901–911 <http://dx.doi.org/10.1002/mbo3.126>.
145. Akhtar S, Khan A, Sohaskey CD, Jagannath C, Sarkar D. 2013. Nitrite reductase NirBD is induced and plays an important role during *in vitro* dormancy of *Mycobacterium tuberculosis*. *J Bacteriol* 195:4592–4599 <http://dx.doi.org/10.1128/JB.00698-13>.
146. Holden JK, Li H, Jing Q, Kang S, Richo J, Silverman RB, Poulos TL. 2013. Structural and biological studies on bacterial nitric oxide synthase inhibitors. *Proc Natl Acad Sci USA* 110:18127–18131 <http://dx.doi.org/10.1073/pnas.1314080110>.
147. MacMicking JD, North RJ, LaCourse R, Mudgett JS, Shah SK, Nathan CF. 1997. Identification of nitric oxide synthase as a protective locus against tuberculosis. *Proc Natl Acad Sci USA* 94:5243–5248 <http://dx.doi.org/10.1073/pnas.94.10.5243>.
148. Rustad TR, Harrell MI, Liao R, Sherman DR. 2008. The enduring hypoxic response of *Mycobacterium tuberculosis*. *PLoS One* 3:e1502 <http://dx.doi.org/10.1371/journal.pone.0001502>.
149. Sakai C, Tomitsuka E, Esumi H, Harada S, Kita K. 2012. Mitochondrial fumarate reductase as a target of chemotherapy: from parasites to cancer cells. *Biochim Biophys Acta* 1820:643–651 <http://dx.doi.org/10.1016/j.bbagen.2011.12.013>.
150. Berney M, Greening C, Conrad R, Jacobs WR Jr, Cook GM. 2014. An obligately aerobic soil bacterium activates fermentative hydrogen production to survive reductive stress during hypoxia. *Proc Natl Acad Sci USA* 111:11479–11484 <http://dx.doi.org/10.1073/pnas.1407034111>.
151. von Ballmoos C, Cook GM, Dimroth P. 2008. Unique rotary ATP synthase and its biological diversity. *Annu Rev Biophys* 37:43–64 <http://dx.doi.org/10.1146/annurev.biophys.37.032807.130018>.
152. Tran SL, Cook GM. 2005. The F_1F_0 -ATP synthase of *Mycobacterium smegmatis* is essential for growth. *J Bacteriol* 187:5023–5028 <http://dx.doi.org/10.1128/JB.187.14.5023-5028.2005>.
153. Friedl P, Hoppe J, Gunsalus RP, Michelsen O, von Meyenburg K, Schairer HU. 1983. Membrane integration and function of the three F_0 subunits of the ATP synthase of *Escherichia coli* K12. *EMBO J* 2:99–103.
154. Santana M, Ionescu MS, Vertes A, Longin R, Kunst F, Danchin A, Glaser P. 1994. *Bacillus subtilis* F_0F_1 ATPase: DNA sequence of the *atp* operon and characterization of *atp* mutants. *J Bacteriol* 176:6802–6811 <http://dx.doi.org/10.1128/jb.176.22.6802-6811.1994>.
155. Cox RA, Cook GM. 2007. Growth regulation in the mycobacterial cell. *Curr Mol Med* 7:231–245 <http://dx.doi.org/10.2174/156652407780598584>.
156. Tran SL, Rao M, Simmers C, Gebhard S, Olsson K, Cook GM. 2005. Mutants of *Mycobacterium smegmatis* unable to grow at acidic pH in the presence of the protonophore carbonyl cyanide m-chlorophenylhydrazone. *Microbiology* 151:665–672 <http://dx.doi.org/10.1099/mic.0.27624-0>.
157. Schnappinger D, Ehrt S, Voskuil MI, Liu Y, Mangan JA, Monahan IM, Dolganov G, Efron B, Butcher PD, Nathan C, Schoolnik GK. 2003. Transcriptional adaptation of *Mycobacterium tuberculosis* within macrophages: insights into the phagosomal environment. *J Exp Med* 198:693–704 <http://dx.doi.org/10.1084/jem.20030846>.
158. Berney M, Cook GM. 2010. Unique flexibility in energy metabolism allows mycobacteria to combat starvation and hypoxia. *PLoS One* 5:e8614 <http://dx.doi.org/10.1371/journal.pone.0008614>.
159. Beste DJ, Laing E, Bonde B, Avignone-Rossa C, Bushell ME, McFadden JJ. 2007. Transcriptomic analysis identifies growth rate modulation as a component of the adaptation of mycobacteria to survival inside the macrophage. *J Bacteriol* 189:3969–3976 <http://dx.doi.org/10.1128/JB.01787-06>.

160. Diacon AH, Donald PR, Pym A, Grobusch M, Patientia RF, Mahanyele R, Bantubani N, Narasimooloo R, De Marez T, van Heeswijk R, Lounis N, Meyvisch P, Andries K, McNeeley DF. 2012. Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multi-drug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance. *Antimicrob Agents Chemother* 56:3271–3276 <http://dx.doi.org/10.1128/AAC.06126-11>.
161. Diacon AH, Pym A, Grobusch M, Patientia R, Rustumjee R, Page-Shipp L, Pistorius C, Krause R, Bogoshi M, Churchyard G, Venter A, Allen J, Palomino JC, De Marez T, van Heeswijk RP, Lounis N, Meyvisch P, Verbeeck J, Parys W, de Beule K, Andries K, McNeeley DF. 2009. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. *N Engl J Med* 360:2397–2405 <http://dx.doi.org/10.1056/NEJMoa0808427>.
162. Diacon AH, Pym A, Grobusch MP, de los Rios JM, Gotuzzo E, Vasilyeva I, Leimane V, Andries K, Bakare N, De Marez T, Haxaire-Theeuwes M, Lounis N, Meyvisch P, De Paepe E, van Heeswijk RP, Dannemann B, TMC207-C208 Study Group. 2014. Multidrug-resistant tuberculosis and culture conversion with bedaquiline. *N Engl J Med* 371:723–732 <http://dx.doi.org/10.1056/NEJMoa1313865>.
163. Haagsma AC, Podasca I, Koul A, Andries K, Guillemont J, Lill H, Bald D. 2011. Probing the interaction of the diarylquinoline TMC207 with its target mycobacterial ATP synthase. *PLoS One* 6:e23575 <http://dx.doi.org/10.1371/journal.pone.0023575>.
164. Lu P, Lill H, Bald D. 2014. ATP synthase in mycobacteria: special features and implications for a function as drug target. *Biochim Biophys Acta* 1837:1208–1218 <http://dx.doi.org/10.1016/j.bbabi.2014.01.022>.
165. Frampton R, Aggio RB, Villas-Bôas SG, Arcus VL, Cook GM. 2012. Toxin-antitoxin systems of *Mycobacterium smegmatis* are essential for cell survival. *J Biol Chem* 287:5340–5356 <http://dx.doi.org/10.1074/jbc.M111.286856>.
166. Lobritz MA, Belenky P, Porter CB, Gutierrez A, Yang JH, Schwarz EG, Dwyer DJ, Khalil AS, Collins JJ. 2015. Antibiotic efficacy is linked to bacterial cellular respiration. *Proc Natl Acad Sci USA* 112:8173–8180 <http://dx.doi.org/10.1073/pnas.1509743112>.
167. Meganathan R. 2001. Biosynthesis of menaquinone (vitamin K2) and ubiquinone (coenzyme Q): a perspective on enzymatic mechanisms. *Vitam Horm* 61:173–218 [http://dx.doi.org/10.1016/S0083-6729\(01\)61006-9](http://dx.doi.org/10.1016/S0083-6729(01)61006-9).